BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215-1219. [PMID: 10094967 DOI: 10.1002/hep.510290401] [Cited by in Crossref: 470] [Cited by in F6Publishing: 459] [Article Influence: 20.4] [Reference Citation Analysis]
Number Citing Articles
1 Wang C, Cheng P, Kao J. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216-30. [DOI: 10.1111/apt.15575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
2 Cholet F, Nousbaum J, Richecœur M, Oger E, Cauvin J, Lagarde N, Robaszkiewicz M, Gouérou H. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroentérologie Clinique et Biologique 2004;28:272-8. [DOI: 10.1016/s0399-8320(04)94918-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
3 Falize L, Guillygomarc'h A, Perrin M, Lainé F, Guyader D, Brissot P, Turlin B, Deugnier Y. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006;44:472-477. [PMID: 16871557 DOI: 10.1002/hep.21260] [Cited by in Crossref: 149] [Cited by in F6Publishing: 115] [Article Influence: 9.3] [Reference Citation Analysis]
4 Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54:1003-1008. [PMID: 15951550 DOI: 10.1136/gut.2004.050302] [Cited by in Crossref: 262] [Cited by in F6Publishing: 247] [Article Influence: 15.4] [Reference Citation Analysis]
5 Ghany MG, Seeff LB. Efforts to Define the Natural History of Chronic Hepatitis C Continue. Clinical Gastroenterology and Hepatology 2006;4:1190-2. [DOI: 10.1016/j.cgh.2006.07.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
6 Everhart J, Herion D. 19 Hepatitis C virus infection and alcohol. Hepatitis C. Elsevier; 2000. pp. 363-88. [DOI: 10.1016/s1874-5326(00)80023-x] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
7 Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69. [PMID: 17515890 DOI: 10.1038/ncpendmet0505] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
8 Esmat G, El Akel W, Metwally M, Soliman A, Doss W, Hamid MA, Kamal M, Zalata K, Khattab H, El-Kassas M, Esmat M, Hasan A, El-Raziky M. Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss. Indian J Gastroenterol 2009;28:45-8. [PMID: 19696987 DOI: 10.1007/s12664-009-0016-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
9 Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung RT. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol. 2006;101:983-992. [PMID: 16573786 DOI: 10.1111/j.1572-0241.2006.00461.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
10 Cowin GJ, Jonsson JR, Bauer JD, Ash S, Ali A, Osland EJ, Purdie DM, Clouston AD, Powell EE, Galloway GJ. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging. 2008;28:937-945. [PMID: 18821619 DOI: 10.1002/jmri.21542] [Cited by in Crossref: 138] [Cited by in F6Publishing: 130] [Article Influence: 10.6] [Reference Citation Analysis]
11 Hora C, Negro F, Leandro G, Oneta CM, Rubbia-brandt L, Muellhaupt B, Helbling B, Malinverni R, Gonvers J, Dufour J; the Swiss Hepatitis C Cohort Study Group. Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C: CTGF, steatosis and hepatitis C. Liver International 2008;28:370-6. [DOI: 10.1111/j.1478-3231.2007.01608.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
12 Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol. 2008;43:811-822. [PMID: 19012034 DOI: 10.1007/s00535-008-2213-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 7.4] [Reference Citation Analysis]
13 McPhail J, Sims OT, Guo Y, Wooten D, Herndon JS, Massoud OI. Fibrosis improvement in patients with HCV treated with direct-acting antivirals. Eur J Gastroenterol Hepatol 2021;33:996-1000. [PMID: 32639414 DOI: 10.1097/MEG.0000000000001821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Gill HK, Wu GY. Non-alcoholic fatty liver disease and the metabolic syndrome: Effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J Gastroenterol 2006; 12(3): 345-353 [PMID: 16489632 DOI: 10.3748/wjg.v12.i3.345] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
15 Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H Jr, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat. 2008;15:129-136. [PMID: 18184196 DOI: 10.1111/j.1365-2893.2007.00901.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
16 Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 2001;21:266-271. [PMID: 11454190 DOI: 10.1034/j.1600-0676.2001.021004266.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 101] [Article Influence: 5.0] [Reference Citation Analysis]
17 Akpo EI, Cerri K, Kleintjens J. Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy. Pharmacoeconomics 2015;33:409-22. [PMID: 25577042 DOI: 10.1007/s40273-014-0249-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus: HEPATITIS C VIRUS GUIDANCE PANEL. Hepatology 2015;62:932-54. [DOI: 10.1002/hep.27950] [Cited by in Crossref: 844] [Cited by in F6Publishing: 832] [Article Influence: 120.6] [Reference Citation Analysis]
19 de Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Annals of Hepatology 2003;2:5-11. [DOI: 10.1016/s1665-2681(19)32152-0] [Cited by in Crossref: 45] [Article Influence: 2.4] [Reference Citation Analysis]
20 Werling K, Schaff Z, Dinya E, Tulassay Z. Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary. Pathol Oncol Res 2010;16:149-57. [PMID: 19757200 DOI: 10.1007/s12253-009-9195-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Parise ER, Oliveira AC. [Insulin resistance in chronic hepatitits C]. Arq Gastroenterol. 2007;44:178-184. [PMID: 17962866 DOI: 10.1590/S0004-28032007000200017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Sharma P, Balan V, Hernandez J, Rosati M, Williams J, Rodriguez-Luna H, Schwartz J, Harrison E, Anderson M, Byrne T. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci. 2004;49:25-29. [PMID: 14992430 DOI: 10.1023/b:ddas.0000011597.92851.56] [Cited by in Crossref: 40] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
23 Persico M, Iolascon A. Steatosis as a co-factor in chronic liver diseases. World J Gastroenterol 2010; 16(10): 1171-1176 [PMID: 20222159 DOI: 10.3748/wjg.v16.i10.1171] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
24 Cammà C, Licata A, Cabibbo G, Latteri F, Craxì A. Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother. 2005;6:399-408. [PMID: 15794731 DOI: 10.1517/14656566.6.3.399] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, Makaritsis K, Germenis A, Dalekos GN. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol. 2008;103:605-614. [PMID: 18190648 DOI: 10.1111/j.1572-0241.2007.01729.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
26 Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647-54. [PMID: 15185306 DOI: 10.1002/hep.20251] [Cited by in Crossref: 530] [Cited by in F6Publishing: 456] [Article Influence: 29.4] [Reference Citation Analysis]
27 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
28 Ryan P, Berenguer J, Michelaud D, Miralles P, Bellón JM, Alvarez E, Catalán P, Sánchez-conde M, Resino S. Insulin Resistance Is Associated With Advanced Liver Fibrosis and High Body Mass Index in HIV/HCV-Coinfected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 2009;50:109-10. [DOI: 10.1097/qai.0b013e318186ede8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
29 Machicao VI, Krishna M, Bonatti H, Aqel BA, Nguyen JH, Weigand SD, Rosser BG, Hughes C, Dickson RC. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation: Hepatitis C Recurrence after Liver Transplantation. Liver Transpl 2004;10:599-606. [DOI: 10.1002/lt.20107] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
30 Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29:2309-24. [PMID: 20228847 DOI: 10.1038/onc.2010.36] [Cited by in Crossref: 184] [Cited by in F6Publishing: 173] [Article Influence: 15.3] [Reference Citation Analysis]
31 Heathcote J. Weighty issues in hepatitis C. Gut 2002;51:7-8. [PMID: 12077081 DOI: 10.1136/gut.51.1.7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
32 Clouston AD, Jonsson JR, Powell EE. Chronic hepatitis C and steatosis. Curr hepatitis rep 2004;3:123-8. [DOI: 10.1007/s11901-004-0021-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
33 Howell J, Angus P, Gow P. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transpl Infect Dis. 2014;16:1-16. [PMID: 24372756 DOI: 10.1111/tid.12173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
34 Sakamoto M, Effendi K, Masugi Y. Molecular diagnosis of multistage hepatocarcinogenesis. Jpn J Clin Oncol. 2010;40:891-896. [PMID: 20603246 DOI: 10.1093/jjco/hyq099] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
35 Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47-S56. [PMID: 12407576 DOI: 10.1053/jhep.2002.36993] [Cited by in Crossref: 34] [Cited by in F6Publishing: 102] [Article Influence: 1.7] [Reference Citation Analysis]
36 Rahman SM, Qadri I, Janssen RC, Friedman JE. Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J Lipid Res. 2009;50:2193-2202. [PMID: 19502591 DOI: 10.1194/jlr.m800633-jlr200] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
37 Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, McHutchison JG, Subramanian M, Millington DM, Kelley RI, Patel K. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 2012;56:49-56. [PMID: 22318926 DOI: 10.1002/hep.25631] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 5.3] [Reference Citation Analysis]
38 Falck-ytter Y, Mccullough AJ. The effect of alcohol on body composition. Am J Gastroenterology 2000;95:2156-9. [DOI: 10.1111/j.1572-0241.2000.02295.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
39 Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, Fletcher LM, Powell LW, Jonsson JR. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology. 2005;129:1937-1943. [PMID: 16344062 DOI: 10.1053/j.gastro.2005.09.015] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 7.1] [Reference Citation Analysis]
40 Foxton MR, Quaglia A, Muiesan P, Heneghan MA, Portmann B, Norris S, Heaton ND, O’Grady JG. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2006;6:1922-1929. [PMID: 16780550 DOI: 10.1111/j.1600-6143.2006.01408.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 85] [Article Influence: 6.3] [Reference Citation Analysis]
41 Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, Heaton S, Conrad A, Pockros PJ, McHutchison JG. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40:484-490. [PMID: 15123364 DOI: 10.1016/j.jhep.2003.11.004] [Cited by in Crossref: 273] [Cited by in F6Publishing: 249] [Article Influence: 15.2] [Reference Citation Analysis]
42 Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat. 2007;14:29-35. [PMID: 17212641 DOI: 10.1111/j.1365-2893.2006.00777.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
43 Ioannou GN, Weiss NS, Boyko EJ, Kowdley KV, Kahn SE, Carithers RL, Tsai EC, Dominitz JA. Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. Clinical Gastroenterology and Hepatology 2005;3:67-74. [DOI: 10.1016/s1542-3565(04)00442-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
44 Sebastiani G, Vario A, Ferrari A, Pistis R, Noventa F, Alberti A. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. J Viral Hepat 2006;13:199-205. [PMID: 16475996 DOI: 10.1111/j.1365-2893.2005.00662.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
45 Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone A, Bagni A, Bertolotti M, Ganazzi D, Carulli N. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Digestive and Liver Disease 2002;34:204-11. [DOI: 10.1016/s1590-8658(02)80194-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
46 Kontorinis N, Garas G, Young J, Speers D, Chester BP, Macquillan GC, De Boer B, Chapman MD, Forster E, Jeffrey GP. Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic: IFN & ribavirin therapy for HCV in shared care. Internal Medicine Journal 2003;33:500-4. [DOI: 10.1046/j.1445-5994.2003.00410.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
47 Bressler B. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44. [DOI: 10.1053/jhep.2003.50350] [Cited by in Crossref: 254] [Cited by in F6Publishing: 243] [Article Influence: 13.4] [Reference Citation Analysis]
48 Chon YE, Jung KS, Kim KJ, Joo DJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci 2015;60:234-42. [PMID: 25118979 DOI: 10.1007/s10620-014-3293-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
49 Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, Jonsson JR. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol. 2003;39:1042-1048. [PMID: 14642624 DOI: 10.1016/s0168-8278(03)00463-x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 40] [Article Influence: 6.9] [Reference Citation Analysis]
50 Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, Igura T, Maeda N, Kihara S, Funahashi T, Matsuzawa Y, Shimomura I, Hayashi N. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol. 2007;47:556-564. [PMID: 17459514 DOI: 10.1016/j.jhep.2007.03.020] [Cited by in Crossref: 118] [Cited by in F6Publishing: 121] [Article Influence: 7.9] [Reference Citation Analysis]
51 Seidel N, Volkmann X, Länger F, Flemming P, Manns MP, Schulze-Osthoff K, Bantel H. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology. 2005;42:113-120. [PMID: 15920717 DOI: 10.1002/hep.20747] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 3.1] [Reference Citation Analysis]
52 Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125:1695-1704. [PMID: 14724822 DOI: 10.1053/j.gastro.2003.08.032] [Cited by in Crossref: 503] [Cited by in F6Publishing: 484] [Article Influence: 27.9] [Reference Citation Analysis]
53 Haufroid V, Ligocka D, Wallemacq P, Lison D, Horsmans Y. Comparison of cytochrome P4502E1 (CYP2E1) activity and hepatic and lymphocyte mRNA expression in patients with chronic hepatitis C. Toxicol Lett 2005;155:171-7. [PMID: 15585372 DOI: 10.1016/j.toxlet.2004.09.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
54 Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, Poynard T. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 2006;44:S19-S24. [PMID: 16356583 DOI: 10.1016/j.jhep.2005.11.009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 7.8] [Reference Citation Analysis]
55 Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008;48:723-31. [PMID: 18688878 DOI: 10.1002/hep.22392] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 5.7] [Reference Citation Analysis]
56 Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology. 2006;44:1648-1655. [PMID: 17133473 DOI: 10.1002/hep.21429] [Cited by in Crossref: 100] [Cited by in F6Publishing: 104] [Article Influence: 6.7] [Reference Citation Analysis]
57 Dias Teixeira MC, De Sá Ribeiro MDFG, Gayotto LCDC, Chamone DDAF, Strauss E. Worse quality of life in volunteer blood donors with hepatitis C: QUALITY OF LIFE IN HEPATITIS C. Transfusion 2006;46:278-83. [DOI: 10.1111/j.1537-2995.2006.00712.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
58 Negro F, Clément S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009;16:681-8. [PMID: 19732324 DOI: 10.1111/j.1365-2893.2009.01186.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
59 Kukla M, Adamek B, Waluga M, Zalewska-Ziob M, Kasperczyk J, Gabriel A, Mazur W, Sobala-Szczygieł B, Bułdak RJ, Zajęcki W, Kępa L, Ziora K, Żwirska-Korczala K, Wiczkowski A, Hartleb M. Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C. Biomed Res Int 2014;2014:517820. [PMID: 25121101 DOI: 10.1155/2014/517820] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
60 Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol. 2005;20:1395-1400. [PMID: 16105127 DOI: 10.1111/j.1440-1746.2005.04007.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
61 Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46. [PMID: 12407575 DOI: 10.1002/hep.1840360706] [Cited by in Crossref: 482] [Cited by in F6Publishing: 299] [Article Influence: 24.1] [Reference Citation Analysis]
62 Dai K, Qi JY, Tian DY. Leptin administration exacerbates thioacetamide-induced liver fibrosis in mice. World J Gastroenterol 2005; 11(31): 4822-4826 [PMID: 16097051 DOI: 10.3748/wjg.v11.i31.4822] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
63 García-Compeán D, Jáquez-Quintana JO, González-González JA, Lavalle-González FJ, Villarreal-Pérez JZ, Maldonado-Garza HJ. [Diabetes in liver cirrhosis]. Gastroenterol Hepatol 2013;36:473-82. [PMID: 23628170 DOI: 10.1016/j.gastrohep.2013.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
64 Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clinical Gastroenterology and Hepatology 2004;2:183-97. [DOI: 10.1016/s1542-3565(04)00002-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
65 Romero-Gómez M, Castellano-Megias VM, Grande L, Irles JA, Cruz M, Nogales MC, Alcón JC, Robles A. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol. 2003;98:1135-1141. [PMID: 12809839 DOI: 10.1111/j.1572-0241.2003.07450.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 74] [Article Influence: 3.5] [Reference Citation Analysis]
66 Read SA, Tay E, Shahidi M, George J, Douglas MW. Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. Journal of General Virology 2014;95:1900-10. [DOI: 10.1099/vir.0.065300-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
67 Balasubramaniyan V, Manju V, Nalini N. Effect of leptin administration on plasma and tissue lipids in alcohol induced liver injury. Hum Exp Toxicol 2003;22:149-54. [DOI: 10.1191/0960327103ht337oa] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
68 Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80-87. [PMID: 17187406 DOI: 10.1002/hep.21455] [Cited by in Crossref: 125] [Cited by in F6Publishing: 113] [Article Influence: 8.3] [Reference Citation Analysis]
69 Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, Giudicelli J, Ferrua B, Laffont C, Benzaken S. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat. 2004;11:91-96. [PMID: 14738564 DOI: 10.1046/j.1365-2893.2003.00483.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 3.1] [Reference Citation Analysis]
70 Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 2012;18:1642-51. [PMID: 22529694 DOI: 10.3748/wjg.v18.i14.1642] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 81] [Article Influence: 9.6] [Reference Citation Analysis]
71 Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, Marcellin P, Balart L, Alberti A, Craxì A. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. Hepatology 2004;39:333-42. [DOI: 10.1002/hep.20073] [Cited by in Crossref: 164] [Cited by in F6Publishing: 150] [Article Influence: 9.1] [Reference Citation Analysis]
72 Monto A, Kakar S, Dove LM, Bostrom A, Miller EL, Wright TL. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients. Am J Gastroenterol 2006;101:1509-15. [PMID: 16863554 DOI: 10.1111/j.1572-0241.2006.00613.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
73 Negro F. Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always. Hepatology. 2002;36:1050-1052. [PMID: 12395313 DOI: 10.1053/jhep.2002.37118] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
74 Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 2002;122:1529-32. [PMID: 11984539 DOI: 10.1053/gast.2002.33369] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 3.0] [Reference Citation Analysis]
75 Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, Brun JM, Hillon P. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35:279-283. [PMID: 11580152 DOI: 10.1016/s0168-8278(01)00143-x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 53] [Article Influence: 8.4] [Reference Citation Analysis]
76 Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-597. [PMID: 14762795 DOI: 10.1053/j.gastro.2003.11.020] [Cited by in Crossref: 318] [Cited by in F6Publishing: 297] [Article Influence: 17.7] [Reference Citation Analysis]
77 Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002;17:1136-1143. [PMID: 12453271 DOI: 10.1046/j.1440-1746.2002.02881.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 119] [Article Influence: 7.1] [Reference Citation Analysis]
78 Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F; HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-42. [PMID: 16697727 DOI: 10.1053/j.gastro.2006.03.014] [Cited by in Crossref: 395] [Cited by in F6Publishing: 366] [Article Influence: 24.7] [Reference Citation Analysis]
79 Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006; 12(42): 6756-6765 [PMID: 17106922 DOI: 10.3748/wjg.v12.i42.6756] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 91] [Article Influence: 6.6] [Reference Citation Analysis]
80 Hu KQ, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken JD, Morgan T, Bräu N, Schmidt WN. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci. 2007;52:570-578. [PMID: 17226072 DOI: 10.1007/s10620-006-9418-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
81 Asano T, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T, Ohnishi S. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol. 2009;24:1669-1676. [PMID: 19788607 DOI: 10.1111/j.1440-1746.2009.06039.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
82 Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-264; quiz 214-217. [PMID: 16401486 DOI: 10.1053/j.gastro.2005.11.010] [Cited by in Crossref: 261] [Cited by in F6Publishing: 246] [Article Influence: 16.3] [Reference Citation Analysis]
83 Hézode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat. 2004;11:455-458. [PMID: 15357652 DOI: 10.1111/j.1365-2893.2004.00528.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 4.2] [Reference Citation Analysis]
84 Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117-1123. [PMID: 10833486 DOI: 10.1016/s0016-5085(00)70364-7] [Cited by in Crossref: 628] [Cited by in F6Publishing: 195] [Article Influence: 28.5] [Reference Citation Analysis]
85 Hayman AV, Sofair AN, Manos MM, Thomas A, Terrault N, Ness GV, Stabach N, Robert M, Rumore G, Corless C, Bell B, Bialek S, Zaman A. Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C. Medicine (Baltimore) 2009;88:302-6. [PMID: 19745689 DOI: 10.1097/MD.0b013e3181b954f4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
86 Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164-2170. [PMID: 23280550 DOI: 10.1002/hep.26218] [Cited by in Crossref: 307] [Cited by in F6Publishing: 293] [Article Influence: 34.1] [Reference Citation Analysis]
87 Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut. 2006;55:123-130. [PMID: 16344578 DOI: 10.1136/gut.2005.069757] [Cited by in Crossref: 257] [Cited by in F6Publishing: 241] [Article Influence: 16.1] [Reference Citation Analysis]
88 Kamali L, Adibi A, Ebrahimian S, Jafari F, Sharifi M. Diagnostic Performance of Ultrasonography in Detecting Fatty Liver Disease in Comparison with Fibroscan in People Suspected of Fatty Liver. Adv Biomed Res 2019;8:69. [PMID: 31897407 DOI: 10.4103/abr.abr_114_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
89 Turlin B, Ramm GA, Purdie DM, Lainé F, Perrin M, Deugnier Y, Macdonald GA. Assessment of hepatic steatosis: comparison of quantitative and semiquantitative methods in 108 liver biopsies: Assessment of hepatic steatosis. Liver International 2009;29:530-5. [DOI: 10.1111/j.1478-3231.2008.01874.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
90 Khouri ST, Perez RM, de Oliveira PM, Figueiredo VM, Barbosa DV, Lanzoni VP, Silva AE, Ferraz ML. Rebiopsy in patients with untreated hepatitis C: a useful procedure. J Clin Gastroenterol 2006;40:347-52. [PMID: 16633108 DOI: 10.1097/01.mcg.0000210100.36500.3f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
91 Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC; Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004;53:451-455. [PMID: 14960533 DOI: 10.1136/gut.2003.021691] [Cited by in Crossref: 193] [Cited by in F6Publishing: 188] [Article Influence: 10.7] [Reference Citation Analysis]
92 Hung CH, Lee CM, Kuo FY, Jiang SR, Hu TH, Chen CH, Wang JH, Lu SN, Eng HL, Changchien CS. Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappaB in chronic hepatitis C. Liver Int 2008;28:339-46. [PMID: 18290776 DOI: 10.1111/j.1478-3231.2008.01676.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
93 Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, Heim MH. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol. 2008;49:429-440. [PMID: 18486982 DOI: 10.1016/j.jhep.2008.04.007] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 4.6] [Reference Citation Analysis]
94 Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol. 2005;100:2717-2723. [PMID: 16393225 DOI: 10.1111/j.1572-0241.2005.00311.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
95 Hansen JF, Juul Nielsen M, Nyström K, Leeming DJ, Lagging M, Norkrans G, Brehm Christensen P, Karsdal M. PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C. Scand J Gastroenterol 2018;53:83-7. [PMID: 29069995 DOI: 10.1080/00365521.2017.1392596] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
96 Sheiner P, Rochon C. Recurrent Hepatitis C After Liver Transplantation: R ECURRENT H EPATITIS C A FTER L IVER T RANSPLANTATION. Mt Sinai J Med 2012;79:190-8. [DOI: 10.1002/msj.21300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
97 Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K, Abiru S, Nakagawa Y, Shigeno M, Miyazoe S, Ichikawa T, Ishikawa H, Nakao K, Eguchi K. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. 2003;97:3036-3043. [PMID: 12784339 DOI: 10.1002/cncr.11427] [Cited by in Crossref: 226] [Cited by in F6Publishing: 223] [Article Influence: 11.9] [Reference Citation Analysis]
98 Metwally MA, Zein CO, Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol. 2004;99:286-291. [PMID: 15046219 DOI: 10.1111/j.1572-0241.2004.04049.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 4.9] [Reference Citation Analysis]
99 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
100 Gabriel A, Ziólkowski A, Radlowski P, Tomaszek K, Dziambor A. Hepatocyte steatosis in HCV patients promotes fibrosis by enhancing TGF-beta liver expression. Hepatol Res 2008;38:141-6. [PMID: 17825062 DOI: 10.1111/j.1872-034X.2007.00258.x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
101 Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol Res. 2010;40:870-877. [PMID: 20887591 DOI: 10.1111/j.1872-034x.2010.00692.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
102 Licata A, Nebbia ME, Cabibbo G, Iacono GL, Barbaria F, Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxì A, Cammà C. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol 2009; 15(17): 2132-2138 [PMID: 19418586 DOI: 10.3748/wjg.15.2132] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
103 Pickhardt PJ, Park SH, Hahn L, Lee SG, Bae KT, Yu ES. Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol. 2012;22:1075-1082. [PMID: 22138733 DOI: 10.1007/s00330-011-2349-2] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
104 Lanternier F, Roulot D, Bentata M, Pol S, Viard J, Gordien E, Jeantils V, Ziol M, Lortholary O. Risks factors of liver fibrosis in a cohort of intravenous drug users coinfected with HIV and HCV at the HAART era: the role of mixed steatosis. Gastroentérologie Clinique et Biologique 2007;31:822-7. [DOI: 10.1016/s0399-8320(07)73972-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis. 2008;12:805-824, ix. [PMID: 18984468 DOI: 10.1016/j.cld.2008.07.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
106 Lang T, Ikejima K, Yoshikawa M, Enomoto N, Iijima K, Kitamura T, Takei Y, Sato N. Leptin facilitates proliferation of hepatic stellate cells through up-regulation of platelet-derived growth factor receptor. Biochem Biophys Res Commun. 2004;323:1091-1095. [PMID: 15381111 DOI: 10.1016/j.bbrc.2004.08.192] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
107 Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T; LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol. 2003;39:1049-1055. [PMID: 14642625 DOI: 10.1016/s0168-8278(03)00456-2] [Cited by in Crossref: 116] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
108 Kim SU, Choi GH, Han WK, Kim BK, Park JY, Kim do Y, Choi JS, Yang SC, Choi EH, Ahn SH. What are ‘true normal’ liver stiffness values using FibroScan?: a prospective study in healthy living liver and kidney donors in South Korea. Liver Int. 2010;30:268-274. [PMID: 19929903 DOI: 10.1111/j.1478-3231.2009.02172.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
109 Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20-29. [PMID: 14681338 DOI: 10.1177/0091270003258669] [Cited by in Crossref: 339] [Cited by in F6Publishing: 333] [Article Influence: 18.8] [Reference Citation Analysis]
110 Saadoun D, Asselah T, Resche-Rigon M, Charlotte F, Bedossa P, Valla D, Piette JC, Marcellin P, Cacoub P. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology. 2006;43:1337-1345. [PMID: 16729318 DOI: 10.1002/hep.21190] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
111 Yu L, Morishima C, Ioannou GN. Dietary cholesterol intake is associated with progression of liver disease in patients with chronic hepatitis C: analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial. Clin Gastroenterol Hepatol. 2013;11:1661-1666.e1-3. [PMID: 23707779 DOI: 10.1016/j.cgh.2013.05.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
112 Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep. 2004;6:22-29. [PMID: 14720450 DOI: 10.1007/s11894-004-0022-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
113 D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005;100:1509-15. [PMID: 15984973 DOI: 10.1111/j.1572-0241.2005.41403.x] [Cited by in Crossref: 162] [Cited by in F6Publishing: 155] [Article Influence: 9.5] [Reference Citation Analysis]
114 Zschiedrich S, Fischer R, Schmitt-Gräff A, Blum H, Breidert M. Acute hepatitis after autologous stem cell transplantation and rapid progression to liver cirrhosis. Eur J Gastroenterol Hepatol 2010;22:1141-4. [PMID: 20463583 DOI: 10.1097/MEG.0b013e32833a064a] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
115 Jonsson JR, Purdie DM, Clouston AD, Powell EE. Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. Mol Diagn Ther 2008;12:209-18. [PMID: 18652517 DOI: 10.1007/BF03256286] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
116 Missiha SB, Ostrowski M, Heathcote EJ. Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors. Gastroenterology 2008;134:1699-714. [DOI: 10.1053/j.gastro.2008.02.069] [Cited by in Crossref: 152] [Cited by in F6Publishing: 127] [Article Influence: 10.9] [Reference Citation Analysis]
117 Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171. [PMID: 15057920 DOI: 10.1002/hep.20119] [Cited by in Crossref: 1226] [Cited by in F6Publishing: 1119] [Article Influence: 68.1] [Reference Citation Analysis]
118 Benini F, Pigozzi MG, Baisini O, Romanini L, Ahmed H, Pozzi A, Ricci C, Lanzini A. Increased serum gamma-glutamyl-transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C. J Gastroenterol Hepatol 2007;22:1621-6. [DOI: 10.1111/j.1440-1746.2006.04733.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
119 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562. [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107] [Cited by in Crossref: 625] [Cited by in F6Publishing: 583] [Article Influence: 69.4] [Reference Citation Analysis]
120 Rodríguez-Torres M. Latinos and chronic hepatitis C: a singular population. Clin Gastroenterol Hepatol 2008;6:484-90. [PMID: 18455693 DOI: 10.1016/j.cgh.2008.02.036] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
121 Yazicioglu G, Isitan F, Altunbas H, Suleymanlar I, Ozdogan M, Balci MK, Karayalcin U. Insulin resistance in chronic hepatitis C. Int J Clin Pract. 2004;58:1020-1022. [PMID: 15605664 DOI: 10.1111/j.1742-1241.2004.00170.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
122 Kukla M, Mazur W, Bułdak RJ, Żwirska-korczala K. Potential Role of Leptin, Adiponectin and Three Novel Adipokines—Visfatin, Chemerin and Vaspin—in Chronic Hepatitis. Mol Med 2011;17:1397-410. [DOI: 10.2119/molmed.2010.00105] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
123 Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, Liang TJ, Hoofnagle JH, Ghany MG. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology. 2006;43:780-787. [PMID: 16557550 DOI: 10.1002/hep.21078] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
124 Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1-16. [PMID: 16436109 DOI: 10.1111/j.0959-9673.2006.00465.x] [Cited by in Crossref: 487] [Cited by in F6Publishing: 482] [Article Influence: 30.4] [Reference Citation Analysis]
125 Silva VA, Ferraz ML, Carvalho-Filho Rd, Lanzoni VP, Silva AE, Silva IS. ASSOCIATION OF THE NUTRITIONAL PROFILE WITH HISTOLOGICAL FINDINGS OF PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION. Arq Gastroenterol 2015;52:315-20. [PMID: 26840474 DOI: 10.1590/S0004-28032015000400012] [Reference Citation Analysis]
126 Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol 2014; 20(36): 12722-12733 [PMID: 25278674 DOI: 10.3748/wjg.v20.i36.12722] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
127 Neau D, Winnock M, Castéra L, Bail BL, Loko M, Géraut L, Dupon M, Ragnaud J, Lacoste D, Lafon M, Bioulac-sage P, Dabis F. Prevalence of and Factors Associated With Hepatic Steatosis in Patients Coinfected With Hepatitis C Virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort. JAIDS Journal of Acquired Immune Deficiency Syndromes 2007;45:168-73. [DOI: 10.1097/qai.0b013e318042e1db] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
128 Castellino S, Lensing S, Riely C, Rai SN, Davila R, Hayden RT, Fleckenstein J, Levstik M, Taylor S, Dean PJ, Kippenbrock S, Pope J, Carr J, Strickland DK, Hudson MM. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. Blood 2004;103:2460-6. [DOI: 10.1182/blood-2003-07-2565] [Cited by in Crossref: 74] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
129 Teoh NC, Farrell GC. Management of chronic hepatitis C virus infection: a new era of disease control. Intern Med J. 2004;34:324-337. [PMID: 15228394 DOI: 10.1111/j.1445-5994.2004.00615.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
130 Piodi A, Chouteau P, Lerat H, Hézode C, Pawlotsky JM. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology. 2008;48:16-27. [PMID: 18570290 DOI: 10.1002/hep.22288] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
131 Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, George J. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002;17:873-81. [PMID: 12164963 DOI: 10.1046/j.1440-1746.2002.02813.x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 120] [Article Influence: 6.2] [Reference Citation Analysis]
132 Elhawary EI, Mahmoud GF, El-Daly MA, Mekky FA, Esmat GG, Abdel-Hamid M. Association of HCV with diabetes mellitus: an Egyptian case-control study. Virol J. 2011;8:367. [PMID: 21791087 DOI: 10.1186/1743-422x-8-367] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
133 Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, Hauser P. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett. 2004;365:87-91. [PMID: 15245784 DOI: 10.1016/j.neulet.2004.04.058] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
134 Orlacchio A, Bolacchi F, Cadioli M, Bergamini A, Cozzolino V, Angelico M, Simonetti G. Evaluation of the severity of chronic hepatitis C with 3-T1H-MR spectroscopy. AJR Am J Roentgenol 2008;190:1331-9. [PMID: 18430852 DOI: 10.2214/AJR.07.2262] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
135 Runyon BA. Ascites and Spontaneous Bacterial Peritonitis. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 1517-1541.e4. [DOI: 10.1016/b978-1-4160-6189-2.00091-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 de Lédinghen V, Combes M, Trouette H, Winnock M, Amouretti M, de Mascarel A, Couzigou P. Should a liver biopsy be done in patients with subclinical chronically elevated transaminases? Eur J Gastroenterol Hepatol 2004;16:879-83. [PMID: 15316412 DOI: 10.1097/00042737-200409000-00011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
137 S??nchez-mu??oz D, Romero-g??mez M, Gonz??lez-escribano MF, Torres B, Castellano-megias VM, G??mez-izquierdo L, Aguilar-reina J, Nu??ez-roldan A. Tumour necrosis factor alpha polymorphisms are not involved in the development of steatosis in chronic hepatitis C: . European Journal of Gastroenterology & Hepatology 2004;16:761-5. [DOI: 10.1097/01.meg.0000108368.19243.97] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
138 Licata A, Nebbia ME, Cabibbo G, Iacono GL, Barbaria F, Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxì A. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol. 2009;15:2132-2138. [PMID: 19418586 DOI: 10.3748/wjg.15.2132.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Bialek SR, Terrault NA. The Changing Epidemiology and Natural History of Hepatitis C Virus Infection. Clinics in Liver Disease 2006;10:697-715. [DOI: 10.1016/j.cld.2006.08.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
140 Nguyen HA, Ho SB. Natural history of chronic hepatitis C: Identifying a window of opportunity for intervention. Journal of Laboratory and Clinical Medicine 2001;137:146-54. [DOI: 10.1067/mlc.2001.113038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
141 Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-9. [PMID: 14960526 DOI: 10.1136/gut.2003.027581] [Cited by in Crossref: 287] [Cited by in F6Publishing: 260] [Article Influence: 15.9] [Reference Citation Analysis]
142 Loftis JM, Morasco BJ, Menasco D, Fuchs D, Strater M, Hauser P. Serum Serotonin Levels are Associated with Antiviral Therapy Outcomes in Patients with Chronic Hepatitis C. Open Infect Dis J 2010;4:132-41. [PMID: 21151716 DOI: 10.2174/1874279301004010132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
143 Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El-Serag HB. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140:1182-1188.e1. [PMID: 21184757 DOI: 10.1053/j.gastro.2010.12.032] [Cited by in Crossref: 265] [Cited by in F6Publishing: 258] [Article Influence: 22.1] [Reference Citation Analysis]
144 Fartoux L, Chazouillères O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology. 2005;41:82-87. [PMID: 15690484 DOI: 10.1002/hep.20519] [Cited by in Crossref: 146] [Cited by in F6Publishing: 129] [Article Influence: 8.6] [Reference Citation Analysis]
145 Afsari A, Lee E, Shokrani B, Boortalary T, Sherif ZA, Nouraie M, Laiyemo AO, Alkhalloufi K, Brim H, Ashktorab H. Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C. Dig Dis Sci 2017;62:2159-65. [PMID: 28612194 DOI: 10.1007/s10620-017-4626-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
146 Posthouwer D, Mauser-Bunschoten EP, Fischer K, VAN Erpecum KJ, DE Knegt RJ. Significant liver damage in patients with bleeding disorders and chronic hepatitis C: non-invasive assessment of liver fibrosis using transient elastography. J Thromb Haemost. 2007;5:25-30. [PMID: 17239163 DOI: 10.1111/j.1538-7836.2006.02272.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
147 Chin M, Hogan C, Nguyen D. The Natural History of Hepatit is C Viral Infection: Clinical Evaluation and Monitoring. MEDJ 2016;3:52-7. [DOI: 10.2174/1874220301603010052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med. 2007;120:829-834. [PMID: 17904449 DOI: 10.1016/j.amjmed.2007.03.025] [Cited by in Crossref: 97] [Cited by in F6Publishing: 78] [Article Influence: 6.5] [Reference Citation Analysis]
149 Hourioux C, Patient R, Morin A, Blanchard E, Moreau A, Trassard S, Giraudeau B, Roingeard P. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut. 2007;56:1302-1308. [PMID: 17213339 DOI: 10.1136/gut.2006.108647] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 4.7] [Reference Citation Analysis]
150 Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer. 2007;109:2490-2496. [PMID: 17487861 DOI: 10.1002/cncr.22701] [Cited by in Crossref: 140] [Cited by in F6Publishing: 123] [Article Influence: 9.3] [Reference Citation Analysis]
151 Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: Prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005;42:310-6. [DOI: 10.1002/hep.20805] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 3.1] [Reference Citation Analysis]
152 Liu J, Chen J, Chen C, Wang J, Lin C, Chen P, Hung C, Kee K, Lee C, Tsai L, Chen S, Lin S, Lu S. Community-based cross-sectional study: The association of lipids with hepatitis C seropositivity and diabetes mellitus: Lipid relation HCV and diabetes mellitus. J Gastroenterol Hepatol 2012;27:1688-94. [DOI: 10.1111/j.1440-1746.2012.07212.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
153 Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis 2007;11:173-89, x. [PMID: 17544978 DOI: 10.1016/j.cld.2007.02.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
154 Patel K, Zekry A, Mchutchison JG. Steatosis and Chronic Hepatitis C Virus Infection: Mechanisms and Significance. Clinics in Liver Disease 2005;9:399-410. [DOI: 10.1016/j.cld.2005.05.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
155 Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40:147-154. [PMID: 14672626 DOI: 10.1016/s0168-8278(03)00479-3] [Cited by in Crossref: 84] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
156 Nguyen HA, Ho SB. Natural history of chronic hepatitis C: Identifying a window of opportunity for intervention. Disease-a-Month 2001;47:593-609. [DOI: 10.1016/s0011-5029(01)90006-9] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
157 Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016;17. [PMID: 27231906 DOI: 10.3390/ijms17060803] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
158 Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol. 2005;5:14. [PMID: 15829009 DOI: 10.1186/1471-230x-5-14] [Cited by in Crossref: 56] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
159 Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol. 2003;18:124-138. [PMID: 12542595 DOI: 10.1046/j.1440-1746.2003.02989.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 146] [Article Influence: 8.4] [Reference Citation Analysis]
160 Mccullough A. Obesity and its nurturing effect on hepatitis C. Hepatology 2003;38:557-9. [DOI: 10.1053/jhep.2003.50413] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
161 Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World J Gastroenterol 2014; 20(23): 7089-7103 [PMID: 24966582 DOI: 10.3748/wjg.v20.i23.7089] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
162 Fabris P, Floreani A, Carlotto A, Giordani MT, Baldo V, Stecca C, Marchioro L, Tramarin A, Bertin T, Negro F, de Lalla F. Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C. Journal of Hepatology 2004;41:644-51. [DOI: 10.1016/j.jhep.2004.06.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
163 Zarski JP, Mc Hutchison J, Bronowicki JP, Sturm N, Garcia-Kennedy R, Hodaj E, Truta B, Wright T, Gish R. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol. 2003;38:307-314. [PMID: 12586296 DOI: 10.1016/s0168-8278(02)00387-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
164 Midgard H, Bang C, Raknerud N, Dalgard O. Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin. Scand J Gastroenterol 2010;45:1503-8. [PMID: 20698740 DOI: 10.3109/00365521.2010.510571] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
165 Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006;101:2629-2640. [PMID: 16952281 DOI: 10.1111/j.1572-0241.2006.00848.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 121] [Article Influence: 7.6] [Reference Citation Analysis]
166 Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut 2005;54:903-6. [PMID: 15951532 DOI: 10.1136/gut.2004.059873] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
167 Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, D’Antò M, Capasso R, Zappia V, Ruggiero G. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology. 2005;41:995-1003. [PMID: 15834927 DOI: 10.1002/hep.20664] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 5.3] [Reference Citation Analysis]
168 Metwally MA, Zein CO, Zein NN. Predictors and Noninvasive Identification of Severe Liver Fibrosis in Patients with Chronic Hepatitis C. Dig Dis Sci 2007;52:582-8. [DOI: 10.1007/s10620-006-9366-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
169 Loy M, Serra G, Chessa L. The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis. J Ultrasound 2016;19:91-8. [PMID: 27298639 DOI: 10.1007/s40477-014-0114-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
170 McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002;8:S7-S13. [PMID: 12362292 DOI: 10.1053/jlts.2002.35856] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
171 Fernández-Rodriguez CM, Gutiérrez ML, Serrano PL, Lledó JL, Santander C, Fernández TP, Tomás E, Cacho G, Nevado M, Casas ML. Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci. 2004;49:1971-1976. [PMID: 15628736 DOI: 10.1007/s10620-004-9603-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
172 Chitturi S, George J. Predictors of liver-related complications in patients with chronic hepatitis C. Ann Med 2000;32:588-91. [PMID: 11209965 DOI: 10.3109/07853890009002028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
173 Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001;34:428-434. [PMID: 11322205 DOI: 10.1016/s0168-8278(00)00036-2] [Cited by in Crossref: 196] [Cited by in F6Publishing: 74] [Article Influence: 9.3] [Reference Citation Analysis]
174 Ikeda A, Shimizu T, Matsumoto Y, Fujii Y, Eso Y, Inuzuka T, Mizuguchi A, Shimizu K, Hatano E, Uemoto S, Chiba T, Marusawa H. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. Gastroenterology 2014;146:222-32.e35. [PMID: 24055508 DOI: 10.1053/j.gastro.2013.09.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
175 Svegliati-Baroni G, Bugianesi E, Bouserhal T, Marini F, Ridolfi F, Tarsetti F, Ancarani F, Petrelli E, Peruzzi E, Lo Cascio M. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut. 2007;56:1296-1301. [PMID: 17392334 DOI: 10.1136/gut.2006.107946] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.2] [Reference Citation Analysis]
176 Doffoël M. Obésité et hépatopathies chroniques alcooliques et virales. Gastroentérologie Clinique et Biologique 2004;28:268-71. [DOI: 10.1016/s0399-8320(04)94917-2] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
177 Lawson A; Trent Hepatitis C Study Group. Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease? J Viral Hepat 2010;17:51-8. [PMID: 19656289 DOI: 10.1111/j.1365-2893.2009.01148.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
178 Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RDG. Lipids and HCV. Semin Immunopathol 2013;35:87-100. [DOI: 10.1007/s00281-012-0356-2] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 7.0] [Reference Citation Analysis]
179 Sanyal AJ. Insulin resistance and tissue repair: a "fato-logical" phenomenon. Gastroenterology 2003;125:1886-9. [PMID: 14724842 DOI: 10.1053/j.gastro.2003.10.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
180 Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat. 2006;13:73-80. [PMID: 16436124 DOI: 10.1111/j.1365-2893.2005.00669.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 6.8] [Reference Citation Analysis]
181 Jármay K, Karácsony G, Nagy A, Schaff Z. Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol 2005; 11(41): 6422-6428 [PMID: 16425410 DOI: 10.3748/wjg.v11.i41.6422] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
182 Antón MD, Roselló E, Gómez F, Paredes JM, López A, Moreno-osset E. Esteatosis hepática en la hepatitis crónica por virus C: estudio de los factores de riesgo y relación con el estadio de fibrosis. Medicina Clínica 2009;132:574-9. [DOI: 10.1016/j.medcli.2008.10.053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
183 Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38:50-56. [PMID: 12829986 DOI: 10.1053/jhep.2003.50291] [Cited by in Crossref: 270] [Cited by in F6Publishing: 249] [Article Influence: 14.2] [Reference Citation Analysis]
184 Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, Kitamura T, Takei Y, Sato N. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002;36:12-21. [PMID: 12085344 DOI: 10.1053/jhep.2002.33684] [Cited by in Crossref: 159] [Cited by in F6Publishing: 166] [Article Influence: 8.0] [Reference Citation Analysis]
185 Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Komatsu N, Umeda N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Asahina Y, Miyake S, Enomoto N, Izumi N. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. Journal of Hepatology 2008;48:736-42. [DOI: 10.1016/j.jhep.2007.12.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
186 Pelletier SJ, Raymond DP, Crabtree TD, Berg CL, Iezzoni JC, Hahn YS, Sawyer RG, Pruett TL. Hepatitis C–induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 2000;32:418-26. [DOI: 10.1053/jhep.2000.9408] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 2.5] [Reference Citation Analysis]
187 Krishan S. Correlation between non-alcoholic fatty liver disease (NAFLD) and dyslipidemia in type 2 diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2016;10:S77-81. [DOI: 10.1016/j.dsx.2016.01.034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
188 Tran HA, Jones TL, Ianna EA, Foy A, Reeves GE. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract 2013;19:292-300. [PMID: 23186968 DOI: 10.4158/EP12195.RA] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
189 Anty R, Gelsi E, Giudicelli J, Mariné-barjoan E, Gual P, Benzaken S, Saint-paul M, Sadoul JL, Huet PM, Tran A. Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses: . European Journal of Gastroenterology & Hepatology 2007;19:671-7. [DOI: 10.1097/meg.0b013e3281532b9a] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
190 Yen Y, Chang K, Tsai M, Tseng P, Lin M, Wu C, Lin J, Hu T, Wang J, Chen C. Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. Journal of the Formosan Medical Association 2018;117:268-75. [DOI: 10.1016/j.jfma.2017.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
191 Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH;  Virahep-C Study Group. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology. 2011;140:469-477. [PMID: 21070775 DOI: 10.1053/j.gastro.2010.11.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
192 Prakoso E, Tirnitz-parker JEE, Clouston AD, Kayali Z, Lee A, Gan EK, Ramm GA, Kench JG, Bowen DG, Olynyk JK, Mccaughan GW, Shackel NA. Analysis of the intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence after liver transplantation: DUCTULAR REACTION IN RECURRENT HCV AFTER TRANSPLANTATION. Liver Transpl 2014;20:1508-19. [DOI: 10.1002/lt.24007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
193 Liu ZW, Zhang N, Han QY, Zeng JT, Chu YL, Qiu JM, Wang YW, Ma LT, Wang XQ. Correlation of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function in Chinese patients with chronic hepatitis C virus infection. World J Gastroenterol 2005; 11(22): 3357-3362 [PMID: 15948239 DOI: 10.3748/wjg.v11.i22.3357] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
194 Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001;35:17-23. [PMID: 11495036 DOI: 10.1016/s0168-8278(01)00066-6] [Cited by in Crossref: 133] [Cited by in F6Publishing: 55] [Article Influence: 6.7] [Reference Citation Analysis]
195 Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 14.4] [Reference Citation Analysis]
196 Cheung O, Sanyal AJ. Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis. 2008;12:573-585, viii-ix. [PMID: 18625429 DOI: 10.1016/j.cld.2008.03.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
197 Hanouneh IA, Feldstein AE, Lopez R, Yerian L, Pillai A, Zein CO, Zein NN. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2008;6:584-589. [PMID: 18455698 DOI: 10.1016/j.cgh.2008.02.034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
198 McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, Schwartzapfel B, Rindler E, Fiorino AM, Zaman MT. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006;43:365-372. [PMID: 16804853 DOI: 10.1086/505495] [Cited by in Crossref: 121] [Cited by in F6Publishing: 105] [Article Influence: 7.6] [Reference Citation Analysis]
199 Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012;107:669-689; quiz 690. [PMID: 22525303 DOI: 10.1038/ajg.2012.48] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 7.2] [Reference Citation Analysis]
200 Alsatie M, Kwo PY, Gingerich JR, Qi R, Eckert G, Cummings OW, Imperiale TF. A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C. J Clin Gastroenterol 2007;41:416-21. [PMID: 17413613 DOI: 10.1097/01.mcg.0000225593.93577.64] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
201 Hézode C, Roudot-thoraval F, Nguyen S, Grenard P, Julien B, Zafrani E, Pawlostky J, Dhumeaux D, Lotersztajn S, Mallat A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63-71. [DOI: 10.1002/hep.20733] [Cited by in Crossref: 199] [Cited by in F6Publishing: 178] [Article Influence: 11.7] [Reference Citation Analysis]
202 Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab. 2002;16:703-716. [PMID: 12468416 DOI: 10.1053/beem.2002.0225] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 4.3] [Reference Citation Analysis]
203 Piccoli Lde Z, Mattos AA, Coral GP, Mattos AZ, Santos DE. Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis. Arq Gastroenterol 2011;48:179-85. [PMID: 21952702 DOI: 10.1590/s0004-28032011000300005] [Reference Citation Analysis]
204 Collier JD, Woodall T, Wight DG, Shore S, Gimson AE, Alexander GJ. Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepat. 2005;12:74-80. [PMID: 15655051 DOI: 10.1111/j.1365-2893.2005.00598.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
205 Ryder SD. Outcome of hepatitis C infection: bleak or benign? J Hepatol. 2007;47:4-6. [PMID: 17512628 DOI: 10.1016/j.jhep.2007.04.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
206 Bethanis SK, Theocharis SE. Leptin in the field of hepatic fibrosis: a pivotal or an incidental player? Dig Dis Sci. 2006;51:1685-1696. [PMID: 16958000 DOI: 10.1007/s10620-006-9126-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
207 Oliveira AC, Parise ER, Catarino RM, Lanzoni V, Leite-Mor MM, Simon KA, Junqueira VB. Insulin resistance and not steatosis is associated with modifications in oxidative stress markers in chronic hepatitis C, non-3 genotype. Free Radic Res 2009;43:1187-94. [PMID: 19905981 DOI: 10.3109/10715760903247249] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
208 Aguila MB, Pinheiro Ada R, Parente LB, Mandarim-de-Lacerda CA. Dietary effect of different high-fat diet on rat liver stereology. Liver Int 2003;23:363-70. [PMID: 14708898 DOI: 10.1034/j.1478-3231.2003.00858.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
209 Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol. 2003;98:2751-2756. [PMID: 14687828 DOI: 10.1111/j.1572-0241.2003.08728.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 70] [Article Influence: 2.4] [Reference Citation Analysis]
210 Rusu E, Jinga M, Enache G, Rusu F, Dragomir AD, Ancuta I, Draguţ R, Parpala C, Nan R, Sima I, Ateia S, Stoica V, Cheţa DM, Radulian G. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial. Nutr J 2013;12:119. [PMID: 23941362 DOI: 10.1186/1475-2891-12-119] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
211 Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, Wu JC, Chang FY, Lee SD. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol. 2001;16:190-195. [PMID: 11207900 DOI: 10.1046/j.1440-1746.2001.02407.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 5.3] [Reference Citation Analysis]
212 Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstål R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. Journal of Hepatology 2002;37:837-42. [DOI: 10.1016/s0168-8278(02)00299-4] [Cited by in Crossref: 198] [Cited by in F6Publishing: 54] [Article Influence: 9.9] [Reference Citation Analysis]
213 Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G. Review article: hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 2005;22 Suppl 2:52-5. [PMID: 16225474 DOI: 10.1111/j.1365-2036.2005.02597.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
214 Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. Hepatitis C and hepatic steatosis. QJM. 2010;103:293-303. [PMID: 20139103 DOI: 10.1093/qjmed/hcp192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
215 Raslan HM, Amr KS, Elhosary YA, Ezzat WM, Abdullah NA, El-Batae HE. Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection. Trans R Soc Trop Med Hyg. 2011;105:396-400. [PMID: 21546048 DOI: 10.1016/j.trstmh.2011.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
216 Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006;43:1177-1186. [PMID: 16729327 DOI: 10.1002/hep.21239] [Cited by in Crossref: 99] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
217 Theise ND, Bodenheimer HC, Ferrell LD. Acute and chronic viral hepatitis. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 361-401. [DOI: 10.1016/b978-0-7020-3398-8.00007-6] [Cited by in Crossref: 6] [Article Influence: 0.6] [Reference Citation Analysis]
218 Bochud P, Cai T, Overbeck K, Bochud M, Dufour J, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology 2009;51:655-66. [DOI: 10.1016/j.jhep.2009.05.016] [Cited by in Crossref: 191] [Cited by in F6Publishing: 173] [Article Influence: 14.7] [Reference Citation Analysis]
219 Lavanchy D. The global burden of hepatitis C. Liver International 2009;29:74-81. [DOI: 10.1111/j.1478-3231.2008.01934.x] [Cited by in Crossref: 882] [Cited by in F6Publishing: 843] [Article Influence: 67.8] [Reference Citation Analysis]
220 Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother. 2011;12:2215-2234. [PMID: 21883025 DOI: 10.1517/14656566.2011.597742] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
221 Feld JJ, Liang TJ. Hepatitis C — identifying patients with progressive liver injury. Hepatology 2006;43:S194-206. [DOI: 10.1002/hep.21065] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 3.9] [Reference Citation Analysis]
222 Fernández-Rodríguez CM, López-Serrano P, Alonso S, Gutiérrez ML, Lledó JL, Pérez-Calle JL, Temiño R, Cacho G, Nevado M, Casas ML, Gasalla JM, Bonet B. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 2006;24:507-12. [PMID: 16886916 DOI: 10.1111/j.1365-2036.2006.03000.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
223 Castéra L, Loko MA, Le Bail B, Coffie P, De Ledinghen V, Trimoulet P, Winnock M, Dabis F, Neau D. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. Aliment Pharmacol Ther. 2007;26:1489-1498. [PMID: 17903235 DOI: 10.1111/j.1365-2036.2007.03533.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
224 Lara J, López-Labrador F, González-Candelas F, Berenguer M, Khudyakov YE. Computational models of liver fibrosis progression for hepatitis C virus chronic infection. BMC Bioinformatics 2014;15 Suppl 8:S5. [PMID: 25081062 DOI: 10.1186/1471-2105-15-S8-S5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
225 Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46. [PMID: 12407575 DOI: 10.1053/jhep.2002.36806] [Cited by in Crossref: 127] [Cited by in F6Publishing: 444] [Article Influence: 6.4] [Reference Citation Analysis]
226 Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013;20:35-40. [PMID: 23723729 DOI: 10.4103/2230-8229.108182] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
227 Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 2002;36:729-736. [PMID: 12198667 DOI: 10.1053/jhep.2002.35064] [Cited by in Crossref: 240] [Cited by in F6Publishing: 237] [Article Influence: 12.0] [Reference Citation Analysis]
228 Adinolfi LE, Utili R, Andreana A, Tripodi MF, Marracino M, Gambardella M, Giordano M, Rugg-iero G. Serum HCV RNA levels correlate with his-tological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci. 2001;46:1677-1683. [PMID: 11508667 DOI: 10.1023/A:1010697319589] [Cited by in Crossref: 59] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
229 Xue X, Lin J, Song Y, Sun X, Zhou H. RNA interference targeting leptin gene effect on hepatic stellate cells. J Huazhong Univ Sci Technolog Med Sci. 2005;25:655-657. [PMID: 16696317 DOI: 10.1007/BF02896162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
230 Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? J Hepatol 2001;35:432-3. [PMID: 11592609 DOI: 10.1016/s0168-8278(01)00107-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
231 Negro F. Steatosis in chronic hepatitis C: friend or foe? Liver Int 2008;28:294-6. [PMID: 18290771 DOI: 10.1111/j.1478-3231.2008.01679.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
232 Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology. 2008;47:2127-2133. [PMID: 18446789 DOI: 10.1002/hep.22269] [Cited by in Crossref: 175] [Cited by in F6Publishing: 155] [Article Influence: 12.5] [Reference Citation Analysis]
233 Depla M, d'Alteroche L, Le Gouge A, Moreau A, Hourioux C, Meunier JC, Gaillard J, de Muret A, Bacq Y, Kazemi F, Avargues A, Roch E, Piver E, Gaudy-Graffin C, Giraudeau B, Roingeard P. Viral sequence variation in chronic carriers of hepatitis C virus has a low impact on liver steatosis. PLoS One 2012;7:e33749. [PMID: 22479436 DOI: 10.1371/journal.pone.0033749] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
234 Hu K, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical Presentation of Chronic Hepatitis C in Patients with End-Stage Renal Disease and on Hemodialysis Versus Those with Normal Renal Function. Am J Gastroenterology 2005;100:2010-8. [DOI: 10.1111/j.1572-0241.2005.51938.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
235 Poynard T. Treatment of cirrhotic patients in the pegylated interferon era. Dig Liver Dis 2004;36 Suppl 3:S344-8. [PMID: 15645665 DOI: 10.1016/s1590-8658(04)80004-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
236 Beard MR, Jones BE. Hepatitis C virus and oxidative stress: a dangerous liaison. Future Virology 2006;1:223-32. [DOI: 10.2217/17460794.1.2.223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
237 Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, Mills AS. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol. 2003;98:2064-2071. [PMID: 14499789 DOI: 10.1111/j.1572-0241.2003.07640.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 109] [Article Influence: 6.4] [Reference Citation Analysis]
238 Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut. 2004;53:406-412. [PMID: 14960525 DOI: 10.1136/gut.2003.018770] [Cited by in Crossref: 194] [Cited by in F6Publishing: 187] [Article Influence: 10.8] [Reference Citation Analysis]
239 Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 15(3): 280-288 [PMID: 19140227 DOI: 10.3748/wjg.15.280] [Cited by in CrossRef: 196] [Cited by in F6Publishing: 180] [Article Influence: 15.1] [Reference Citation Analysis]
240 Sulkowski M, Mast E, Seeff L, Thomas D. Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency Virus. CLIN INFECT DIS 2000;30:S77-84. [DOI: 10.1086/313842] [Cited by in Crossref: 183] [Cited by in F6Publishing: 165] [Article Influence: 8.3] [Reference Citation Analysis]
241 Goulding C, O'brien C, Egan H, Hegarty JE, Mcdonald G, O'farrelly C, White B, Kelleher D, Norris S. The impact of inherited prothrombotic risk factors on individuals chronically infected with hepatitis C virus from a single source. J Viral Hepat 2007;14:255-9. [DOI: 10.1111/j.1365-2893.2006.00790.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
242 Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Oza N, Nakashita S, Hara M, Iwane S, Takahashi H, Akiyama T. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int. 2009;29:213-220. [PMID: 18710430 DOI: 10.1111/j.1478-3231.2008.01853.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
243 Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33:106-115. [PMID: 10905593 DOI: 10.1016/s0168-8278(00)80166-x] [Cited by in Crossref: 394] [Cited by in F6Publishing: 136] [Article Influence: 17.9] [Reference Citation Analysis]
244 Fabris P, Floreani A, Carlotto A, Baldo V, Bozzola L, Giordani MT, Negro F, Rassu M, Tramarin A, Lalla F. Impact of liver steatosis on virological response in elderly Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin. Aliment Pharmacol Ther 2005;21:1173-8. [DOI: 10.1111/j.1365-2036.2005.02452.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
245 Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, Yamashiki N, Yoshida H, Kanai F, Kato N. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6:459-464. [PMID: 18387499 DOI: 10.1016/j.cgh.2008.02.012] [Cited by in Crossref: 102] [Cited by in F6Publishing: 101] [Article Influence: 7.3] [Reference Citation Analysis]
246 Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H. Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Hepatol Res. 2014;44:E137-E144. [PMID: 24125181 DOI: 10.1111/hepr.12258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
247 Giustina RD, Marconcini ML, Bansho ET, Tonon D, Pasinato AP, Dantas-Corrêa EB, Schiavon LL, Narciso-Schiavon JL. Factors associated with steatosis in liver biopsies of individuals with chronic hepatitis C infection in southern Brazil. Arab J Gastroenterol 2015;16:59-62. [PMID: 26169501 DOI: 10.1016/j.ajg.2015.06.002] [Reference Citation Analysis]
248 Bajis S, Grebely J, Hajarizadeh B, Applegate T, Marshall AD, Ellen Harrod M, Byrne J, Bath N, Read P, Edwards M, Gorton C, Hayllar J, Cock V, Peterson S, Thomson C, Weltman M, Jefferies M, Wood W, Haber P, Ezard N, Martinello M, Maher L, Dore GJ; LiveRLife Study Group. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. J Viral Hepat 2020;27:281-93. [PMID: 31698545 DOI: 10.1111/jvh.13233] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
249 Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 2003;125:1053-9. [PMID: 14517789 DOI: 10.1016/s0016-5085(03)01200-9] [Cited by in Crossref: 83] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
250 Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int. 2013;2013:564645. [PMID: 23956991 DOI: 10.1155/2013/564645] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
251 Asselah T, Boudjema H, Francoz C, Sobesky R, Valla D, Belghiti J, Marcellin P, Durand F. Hépatite C et transplantation hépatique. Gastroentérologie Clinique et Biologique 2006;30:1281-95. [DOI: 10.1016/s0399-8320(06)73536-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
252 Kobayashi Y, Kawaguchi Y, Mizuta T, Kuwashiro T, Oeda S, Oza N, Takahashi H, Iwane S, Eguchi Y, Anzai K. Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C. J Gastroenterol. 2011;46:529-535. [PMID: 21046172 DOI: 10.1007/s00535-010-0338-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
253 Valery PC, Powell E, Moses N, Volk ML, McPhail SM, Clark PJ, Martin J. Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. BMJ Open. 2015;5:e007451. [PMID: 25854973 DOI: 10.1136/bmjopen-2014-007451] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
254 Bailey J. An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 2. Alternative Replacement Methods. Altern Lab Anim 2010;38:471-94. [DOI: 10.1177/026119291003800602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
255 Petit JM, Minello A, Jooste V, Bour JB, Galland F, Duvillard L, Verges B, Olsson NO, Gambert P, Hillon P. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. 2005;90:2240-2243. [PMID: 15644404 DOI: 10.1210/jc.2004-1266] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 4.2] [Reference Citation Analysis]
256 McCullough AJ, Falck-Ytter Y. Body composition and hepatic steatosis as precursors for fibrotic liver disease. Hepatology. 1999;29:1328-1330. [PMID: 10094983 DOI: 10.1002/hep.510290451] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 2.2] [Reference Citation Analysis]
257 Mackawy AM, Badawy ME, Megahed OAEY. Angiotensin converting enzyme (ACE D/I) polymorphism and its relation to liver fibrosis progression in Egyptian patients with chronic hepatitis C virus infection. Egyptian Journal of Medical Human Genetics 2012;13:291-9. [DOI: 10.1016/j.ejmhg.2012.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
258 Schult A, Eriksson H, Wallerstedt S, Kaczynski J. Overweight and hypertriglyceridemia are risk factors for liver cirrhosis in middle-aged Swedish men. Scandinavian Journal of Gastroenterology 2011;46:738-44. [DOI: 10.3109/00365521.2011.560679] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
259 Moon J, Kallman J, Winter P, Srishord M, Fang Y, Gerber L, Younossi Z. Disparities in Activity Level and Nutrition Between Patients With Chronic Hepatitis C and Blood Donors. PM&R 2012;4:436-41. [DOI: 10.1016/j.pmrj.2012.02.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
260 Tsochatzis EA, Manolakopoulos S, Papatheodoridis GV, Archimandritis AJ. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol. 2009;44:6-14. [PMID: 18661429 DOI: 10.1080/00365520802273058] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
261 Petta S, Amato M, Cabibi D, Cammà C, Di Marco V, Giordano C, Galluzzo A, Craxì A. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010;52:1543-52. [DOI: 10.1002/hep.23859] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.8] [Reference Citation Analysis]
262 Maor-kendler Y, Batts KP, Burgart LJ, Wiesner RH, Krom RA, Rosen CB, Charlton MR. COMPARATIVE ALLOGRAFT HISTOLOGY AFTER LIVER TRANSPLANTATION FOR CRYPTOGENIC CIRRHOSIS, ALCOHOL, HEPATITIS C, AND CHOLESTATIC LIVER DISEASES1: . Transplantation 2000;70:292-7. [DOI: 10.1097/00007890-200007270-00009] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 2.6] [Reference Citation Analysis]
263 Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93:S74-S80. [PMID: 18987273 DOI: 10.1210/jc.2008-1399] [Cited by in Crossref: 176] [Cited by in F6Publishing: 167] [Article Influence: 13.5] [Reference Citation Analysis]
264 Friedenberg F, Pungpapong S, Zaeri N, Braitman LE. The impact of diabetes and obesity on liver histology in patients with hepatitis C. Diabetes Obes Metab 2003;5:150-5. [PMID: 12681021 DOI: 10.1046/j.1463-1326.2003.00256.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
265 Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K. Correlation of hepatic steatosis with body mass index, serum ferritin level and hepatic fibrosis in Japanese patients with chronic hepatitis C. Hepatology Research 2007;37:263-9. [DOI: 10.1111/j.1872-034x.2007.00038.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
266 Sato M, Kondo M, Tateishi R, Fujiwara N, Kato N, Yoshida H, Taguri M, Koike K. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One 2014;9:e91822. [PMID: 24637774 DOI: 10.1371/journal.pone.0091822] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
267 Andrade RJ, García-escaño MD. Esteatosis hepática. Medicina Clínica 2000;114:574-6. [DOI: 10.1016/s0025-7753(00)71367-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
268 Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat. 2009;16:492-499. [PMID: 19200134 DOI: 10.1111/j.1365-2893.2009.01098.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
269 Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, Rebucci C, Cividini A, Pizzolanti G, Minola E. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. 2006;43:64-71. [PMID: 16374856 DOI: 10.1002/hep.20983] [Cited by in Crossref: 117] [Cited by in F6Publishing: 113] [Article Influence: 7.3] [Reference Citation Analysis]
270 Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F, Budillon G, Cimino L, Di Carlo A, Pia Di Marino M, Morisco F, Picciotto F, Terracciano L, Vecchione R, Verde V, Del Vecchio Blanco C. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. Journal of Hepatology 2001;35:568-74. [DOI: 10.1016/s0168-8278(01)00192-1] [Cited by in Crossref: 96] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
271 Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol. 2003;38 Suppl 1:S104-S118. [PMID: 12591189 DOI: 10.1016/s0168-8278(03)00008-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
272 Guidi M, Muratori P, Granito A, Muratori L, Pappas G, Lenzi M, Bianchi FB. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Aliment Pharmacol Ther. 2005;22:943-949. [PMID: 16268968 DOI: 10.1111/j.1365-2036.2005.02679.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
273 Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, Daïkha H, Vidaud D, Martinot M, Vidaud M, Degott C, Valla D, Marcellin P. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003;52:1638-43. [PMID: 14570735 DOI: 10.1136/gut.52.11.1638] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 4.4] [Reference Citation Analysis]
274 Fukushima J, Kamada Y, Matsumoto H, Yoshida Y, Ezaki H, Takemura T, Saji Y, Igura T, Tsutsui S, Kihara S, Funahashi T, Shimomura I, Tamura S, Kiso S, Hayashi N. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res. 2009;39:724-738. [PMID: 19473437 DOI: 10.1111/j.1872-034x.2009.00509.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
275 Macdonald GA, Powell LW. More clues to the relationship between hepatic iron and steatosis: An association with insulin resistance? Gastroenterology 1999;117:1241-4. [PMID: 10535890 DOI: 10.1016/s0016-5085(99)70412-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
276 Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int. 2009;29 Suppl 1:89-99. [PMID: 19207971 DOI: 10.1111/j.1478-3231.2008.01927.x] [Cited by in Crossref: 161] [Cited by in F6Publishing: 151] [Article Influence: 12.4] [Reference Citation Analysis]
277 Hellerbrand C. Pathophysiological similarities and synergisms in alcoholic and non-alcoholic steatohepatitis. Dig Dis. 2010;28:783-791. [PMID: 21525763 DOI: 10.1159/000324286] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
278 Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004;38:705-709. [PMID: 15319656 DOI: 10.1097/01.mcg.0000135372.10846.2a] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 3.8] [Reference Citation Analysis]
279 Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc’h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol. 2001;116:263-270. [PMID: 11488074 DOI: 10.1309/wwne-kw2c-4ktw-ptj5] [Cited by in Crossref: 97] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
280 Iwasa M, Hara N, Iwata K, Ishidome M, Sugimoto R, Tanaka H, Fujita N, Kobayashi Y, Takei Y. Restriction of calorie and iron intake results in reduction of visceral fat and serum alanine aminotransferase and ferritin levels in patients with chronic liver disease: Lifestyle modifications in chronic liver disease. Hepatology Research 2010;40:1188-94. [DOI: 10.1111/j.1872-034x.2010.00724.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
281 Won Y, Song J, Lim J, Lee M, Moon O, Kim H, Son H, Kwon H. Genetically obese (ob/ob) mice are resistant to the lethal effects of thioacetamide hepatotoxicity. Toxicology and Applied Pharmacology 2016;291:38-45. [DOI: 10.1016/j.taap.2015.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
282 Martin-carbonero L, Soriano V. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. AIDS 2005;19:621-3. [DOI: 10.1097/01.aids.0000163939.08811.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
283 Adinolfi LE, Restivo L, Marrone A. The predictive value of steatosis in hepatitis C virus infection. Expert Rev Gastroenterol Hepatol. 2013;7:205-213. [PMID: 23445230 DOI: 10.1586/egh.13.7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
284 Ripoli M, Pazienza V. Impact of HCV genetic differences on pathobiology of disease. Expert Rev Anti Infect Ther 2011;9:747-59. [PMID: 21905784 DOI: 10.1586/eri.11.94] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
285 Pavlidis C, Panoutsopoulos GI, Tiniakos D, Koutsounas S, Vlachogiannakos J, Zouboulis-Vafiadis I. Serum leptin and ghrelin in chronic hepatitis C patients with steatosis. World J Gastroenterol 2011; 17(46): 5097-5104 [PMID: 22171144 DOI: 10.3748/wjg.v17.i46.5097] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
286 Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002;122:1399-410. [PMID: 11984526 DOI: 10.1053/gast.2002.32995] [Cited by in Crossref: 271] [Cited by in F6Publishing: 266] [Article Influence: 13.6] [Reference Citation Analysis]
287 Han SB, Martin P. Diabetes Mellitus: A Predictor of Cirrhosis in Chronic Viral Hepatitis. Journal of Clinical Gastroenterology 2000;30:227-8. [DOI: 10.1097/00004836-200004000-00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
288 Masarone M, La Mura V, Bruno S, Gaeta GB, Vecchione R, Carrino F, Moschella F, Torella R, Persico M. Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. J Viral Hepat. 2007;14:714-720. [PMID: 17875006 DOI: 10.1111/j.1365-2893.2007.00861.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
289 Ong JP, Younossi ZM. Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2005;9:617-34. [DOI: 10.1016/j.cld.2005.07.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
290 Solis-herruzo JA, Pérez-carreras M, Rivas E, Fernández-vázquez I, Garfia C, Bernardos E, Castellano G, Colina F. Factors Associated with the Presence of Nonalcoholic Steatohepatitis in Patients with Chronic Hepatitis C. Am J Gastroenterol 2005;100:1091-8. [DOI: 10.1111/j.1572-0241.2005.41059.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
291 Magri MC, Alvarez MSM, Iogi AA, Alves GM, Manchiero C, Dantas BP, Prata TVG, Nunes AKDS, Tengan FM. Study of CXCL9-11 gene polymorphisms in liver fibrosis among patients with chronic hepatitis C. Pathog Dis 2021;79:ftab007. [PMID: 33476381 DOI: 10.1093/femspd/ftab007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
292 Martino VD, Lebray P, Myers RP, Pannier E, Paradis V, Charlotte F, Moussalli J, Thabut D, Buffet C, Poynard T. Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure. Hepatology 2004;40:1426-33. [DOI: 10.1002/hep.20463] [Cited by in Crossref: 172] [Cited by in F6Publishing: 147] [Article Influence: 9.6] [Reference Citation Analysis]
293 Cheung KJ, Libbrecht L, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol. 2010;22:1066-1073. [PMID: 20186066 DOI: 10.1097/MEG.0b013e328337d602] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
294 Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol. 2002;37:206-213. [PMID: 12127425 DOI: 10.1016/s0168-8278(02)00102-2] [Cited by in Crossref: 281] [Cited by in F6Publishing: 104] [Article Influence: 14.8] [Reference Citation Analysis]
295 Gonçalves D, Lima C, Ferreira P, Costa P, Costa A, Figueiredo W, Cesar T. Orange juice as dietary source of antioxidants for patients with hepatitis C under antiviral therapy. Food Nutr Res 2017;61:1296675. [PMID: 28469541 DOI: 10.1080/16546628.2017.1296675] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
296 Geng N, Xin YN, Xia HH, Jiang M, Wang J, Liu Y, Chen LZ, Xuan SY. Association of PNPLA3 I148M Variant With Chronic Viral Hepatitis, Autoimmune Liver Diseases and Outcomes of Liver Transplantation. Hepat Mon 2015;15:e26459. [PMID: 26034504 DOI: 10.5812/hepatmon.15(4)2015.26459] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
297 Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94. [PMID: 12077098 DOI: 10.1136/gut.51.1.89] [Cited by in Crossref: 195] [Cited by in F6Publishing: 181] [Article Influence: 9.8] [Reference Citation Analysis]
298 Akpo EI, Sbarigia U, Wan G, Kleintjens J. Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. Drugs R D 2015;15:335-49. [PMID: 26416653 DOI: 10.1007/s40268-015-0109-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
299 Negro F. Insulin resistance and HCV: will new knowledge modify clinical management? J Hepatol 2006;45:514-9. [PMID: 16901576 DOI: 10.1016/j.jhep.2006.07.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
300 Zhu AX, Chung RT. Hepatic steatosis in patients with chronic hepatitis C virus infection: Another risk factor for hepatocellular carcinoma? Cancer 2003;97:2948-50. [DOI: 10.1002/cncr.11440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
301 Matos CA, Perez RM, Pacheco MS, Figueiredo-Mendes CG, Lopes-Neto E, Oliveira EB, Lanzoni VP, Silva AE, Ferraz ML. Steatosis in chronic hepatitis C: relationship to the virus and host risk factors. J Gastroenterol Hepatol. 2006;21:1236-1239. [PMID: 16872303 DOI: 10.1111/j.1440-1746.2006.04308.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
302 Watt GP, Vatcheva KP, Beretta L, Pan JJ, Fallon MB, McCormick JB, Fisher-Hoch SP. Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes. Epidemiol Infect 2016;144:297-305. [PMID: 26088260 DOI: 10.1017/S0950268815001247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
303 Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miailhes P, Valantin MA, Charlotte F, Bertheau P, Molina JM, Katlama C, Caumes E. Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. BMC Res Notes 2012;5:180. [PMID: 22490728 DOI: 10.1186/1756-0500-5-180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
304 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD;  American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49:1017-1044. [PMID: 19243014 DOI: 10.1002/hep.22742] [Cited by in Crossref: 1217] [Cited by in F6Publishing: 1042] [Article Influence: 93.6] [Reference Citation Analysis]
305 Abid K, Pazienza V, de Gottardi A, Rubbia-Brandt L, Conne B, Pugnale P, Rossi C, Mangia A, Negro F. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol. 2005;42:744-751. [PMID: 15826725 DOI: 10.1016/j.jhep.2004.12.034] [Cited by in Crossref: 119] [Cited by in F6Publishing: 122] [Article Influence: 7.0] [Reference Citation Analysis]
306 Sebastiani G, Walker AP. HFE gene in primary and secondary hepatic iron overload. World J Gastroenterol 2007; 13(35): 4673-4689 [PMID: 17729389 DOI: 10.3748/wjg.v13.i35.4673] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
307 Verma S, Goldin RD, Main J. Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis? BMC Res Notes 2008;1:46. [PMID: 18710499 DOI: 10.1186/1756-0500-1-46] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
308 Delgado-borrego A, Jonas MM. Treatment options for hepatitis C infection in children. Curr Treat Options Gastro 2004;7:373-9. [DOI: 10.1007/s11938-004-0050-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
309 Asselah T, Boyer N, Marcellin P. Steatosis in hepatitis C: What does it mean? Curr hepatitis rep 2003;2:137-44. [DOI: 10.1007/s11901-003-0015-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
310 Brunt EM. Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation. Hepatol Commun. 2017;1:370-378. [PMID: 29404465 DOI: 10.1002/hep4.1055] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
311 Petta S, Amato MC, Di Marco V, Cammà C, Pizzolanti G, Barcellona MR, Cabibi D, Galluzzo A, Sinagra D, Giordano C. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:238-247. [PMID: 22117531 DOI: 10.1111/j.1365-2036.2011.04929.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis]
312 Delgado-Borrego A, Liu YS, Jordan SH, Agrawal S, Zhang H, Christofi M, Casson D, Cosimi AB, Chung RT. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl. 2008;14:193-201. [PMID: 18236394 DOI: 10.1002/lt.21267] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
313 García González N, Prieto Valtueña J. Virus C, hierro y azúcar. Medicina Clínica 2000;115:25-6. [DOI: 10.1016/s0025-7753(00)71452-7] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
314 Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol. 2004;19:368-374. [PMID: 15012772 DOI: 10.1111/j.1440-1746.2003.03252.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 5.6] [Reference Citation Analysis]
315 Batty GD, Shipley MJ, Kivimaki M, Barzi F, Smith GD, Mitchell R, Marmot MG, Huxley R. Obesity and overweight in relation to liver disease mortality in men: 38 year follow-up of the original Whitehall study. Int J Obes (Lond) 2008;32:1741-4. [PMID: 18794897 DOI: 10.1038/ijo.2008.162] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
316 Taouli B, Ehman RL, Reeder SB. Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol. 2009;193:14-27. [PMID: 19542391 DOI: 10.2214/ajr.09.2601] [Cited by in Crossref: 128] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
317 Cheung JS, Fan SJ, Gao DS, Chow AM, Yang J, Man K, Wu EX. In Vivo Lipid Profiling Using Proton Magnetic Resonance Spectroscopy in an Experimental Liver Fibrosis Model. Academic Radiology 2011;18:377-83. [DOI: 10.1016/j.acra.2010.10.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
318 Clark PJ, Thompson AJ, Zhu Q, Vock DM, Zhu M, Patel K, Harrison SA, Naggie S, Ge D, Tillmann HL. The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci. 2012;57:2213-2221. [PMID: 22543885 DOI: 10.1007/s10620-012-2171-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
319 Minola E, Prati D, Suter F, Maggiolo F, Caprioli F, Sonzogni A, Fraquelli M, Paggi S, Conte D. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood. 2002;99:4588-4591. [PMID: 12036892 DOI: 10.1182/blood-2001-12-0192] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 5.2] [Reference Citation Analysis]
320 Toniutto P, Fabris C, Avellini C, Minisini R, Bitetto D, Rossi E, Smirne C, Pirisi M. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol 2005; 11(38): 5944-5950 [PMID: 16273604 DOI: 10.3748/wjg.v11.i38.5944] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
321 Persico M, Masarone M, Mura VL, Persico E, Moschella F, Svelto M, Bruno S, Torella R. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: Differences and similarities. World J Gastroenterol 2009; 15(4): 462-466 [PMID: 19152451 DOI: 10.3748/wjg.15.462] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
322 Brunt EM, Tiniakos DG. Steatosis, steatohepatitis: Review of effects on chronic hepatitis C. Current Hepatitis Reports 2002;1:38-44. [DOI: 10.1007/s11901-002-0007-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
323 Alavian SM, Hajarizadeh B, Nematizadeh F, Larijani B. Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease. BMC Endocr Disord 2004;4:4. [PMID: 15555059 DOI: 10.1186/1472-6823-4-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
324 McLauchlan J. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat. 2000;7:2-14. [PMID: 10718937 DOI: 10.1046/j.1365-2893.2000.00201.x] [Cited by in Crossref: 217] [Cited by in F6Publishing: 214] [Article Influence: 9.9] [Reference Citation Analysis]
325 McPherson S, Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE. Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. J Hepatol 2008;49:1046-54. [PMID: 18752865 DOI: 10.1016/j.jhep.2008.06.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
326 Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C--natural history and cofactors. Aliment Pharmacol Ther. 2005;22 Suppl 2:74-78. [PMID: 16225479 DOI: 10.1111/j.1365-2036.2005.02602.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
327 Zeremski M, Dimova RB, Pillardy J, de Jong YP, Jacobson IM, Talal AH. Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection. J Infect Dis 2016;214:1164-70. [PMID: 27485356 DOI: 10.1093/infdis/jiw332] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
328 Milano M, Aghemo A, Mancina RM, Fischer J, Dongiovanni P, De Nicola S, Fracanzani AL, D’Ambrosio R, Maggioni M, De Francesco R. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology. 2015;62:111-117. [PMID: 25820484 DOI: 10.1002/hep.27811] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
329 Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, Tubiana R, Poynard T, Katlama C, Lombès A. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology. 2009;49:436-442. [PMID: 19085967 DOI: 10.1002/hep.22665] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 8.2] [Reference Citation Analysis]
330 Rawlins SR, El-Zammar O, Zinkievich JM, Newman N, Levine RA. Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C. Dig Dis Sci 2010;55:2049-57. [PMID: 20458626 DOI: 10.1007/s10620-010-1254-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
331 Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, Powell EE, Tilg H. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol. 2005;43:929-936. [PMID: 16139921 DOI: 10.1016/j.jhep.2005.05.030] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 4.5] [Reference Citation Analysis]
332 Machado MV, Cortez-pinto H. Insulin resistance and steatosis in chronic hepatitis C. Annals of Hepatology 2009;8:S67-75. [DOI: 10.1016/s1665-2681(19)31829-0] [Cited by in Crossref: 25] [Article Influence: 1.9] [Reference Citation Analysis]
333 Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR, Powell EE. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology. 2004;39:1230-1238. [PMID: 15122751 DOI: 10.1002/hep.20179] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 5.4] [Reference Citation Analysis]
334 Aspinall RJ, Pockros PJ. The management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther. 2004;20:917-929. [PMID: 15521838 DOI: 10.1111/j.1365-2036.2004.02192.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
335 Yin Y, Li Y, Shao L, Yuan S, Liu B, Lin S, Yang Y, Tang S, Meng F, Wu Y, Chen Y, Li B, Zhu Q, Qi X. Effect of Body Mass Index on the Prognosis of Liver Cirrhosis. Front Nutr 2021;8:700132. [PMID: 34490322 DOI: 10.3389/fnut.2021.700132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
336 Sevastianos VA, Hadziyannis SJ. Nonalcoholic fatty liver disease: from clinical recognition to treatment. Expert Rev Gastroenterol Hepatol. 2008;2:59-79. [PMID: 19072371 DOI: 10.1586/17474124.2.1.59] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
337 Ramnath D, Irvine KM, Lukowski SW, Horsfall LU, Loh Z, Clouston AD, Patel PJ, Fagan KJ, Iyer A, Lampe G, Stow JL, Schroder K, Fairlie DP, Powell JE, Powell EE, Sweet MJ. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. JCI Insight 2018;3:120274. [PMID: 30046009 DOI: 10.1172/jci.insight.120274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
338 Dyson JK, Mcpherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013;66:1033-45. [DOI: 10.1136/jclinpath-2013-201620] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
339 Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356-1362. [PMID: 10573511 DOI: 10.1002/hep.510300604] [Cited by in Crossref: 1033] [Cited by in F6Publishing: 979] [Article Influence: 44.9] [Reference Citation Analysis]
340 Gomes de Sá Ribeiro MDF, da Costa Gayotto LC, de Alencar Fischer Chamone D, Strauss E. Alcoholic intake predisposes to more interface hepatitis in chronic hepatitis C. Annals of Hepatology 2005;4:176-83. [DOI: 10.1016/s1665-2681(19)32062-9] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
341 Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C. Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Clinical Gastroenterology and Hepatology 2007;5:245-54. [DOI: 10.1016/j.cgh.2006.11.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
342 Gochee PA, Jonsson JR, Clouston AD, Pandeya N, Purdie DM, Powell EE. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol. 2003;18:386-392. [PMID: 12653886 DOI: 10.1046/j.1440-1746.2003.02984.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 2.9] [Reference Citation Analysis]
343 Jon AF, Cheema AR, Khan AN, Raptopoulos V, Hauser T, Nasser I, Welty FK, Karellas A, Clouse ME. Assessment of liver fat in an obese patient population using noncontrast CT fat percent index. Clin Imaging 2014;38:259-64. [PMID: 24559751 DOI: 10.1016/j.clinimag.2014.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
344 Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol 2009; 15(35): 4356-4364 [PMID: 19764085 DOI: 10.3748/wjg.15.4356] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
345 Forman LM. Metabolic syndrome in liver transplantation: The elephant in the room. Liver Transpl 2008;14:1245-8. [DOI: 10.1002/lt.21591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
346 Jacobs JM, Diamond DL, Chan EY, Gritsenko MA, Qian W, Stastna M, Baas T, Camp DG 2nd, Carithers RL Jr, Smith RD, Katze MG. Proteome analysis of liver cells expressing a full-length hepatitis C virus (HCV) replicon and biopsy specimens of posttransplantation liver from HCV-infected patients. J Virol 2005;79:7558-69. [PMID: 15919910 DOI: 10.1128/JVI.79.12.7558-7569.2005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
347 Pickhardt PJ, Hahn L, del Rio AM, Park SH, Reeder SB, Said A. Natural History of Hepatic Steatosis: Observed Outcomes for Subsequent Liver and Cardiovascular Complications. American Journal of Roentgenology 2014;202:752-8. [DOI: 10.2214/ajr.13.11367] [Cited by in Crossref: 44] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
348 Cortez-Pinto H. Concluding remarks: metabolic syndrome, liver and HCV. Aliment Pharmacol Ther. 2005;22 Suppl 2:83-85. [PMID: 16225481 DOI: 10.1111/j.1365-2036.2005.02604.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
349 Giannattasio A, Spagnuolo MI, Sepe A, Valerio G, Vecchione R, Vegnente A, Iorio R. Is HCV infection associated with liver steatosis also in children? Journal of Hepatology 2006;45:758-9. [DOI: 10.1016/j.jhep.2006.08.006] [Reference Citation Analysis]
350 Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005;42:5-13. [PMID: 15962320 DOI: 10.1002/hep.20750] [Cited by in Crossref: 250] [Cited by in F6Publishing: 243] [Article Influence: 14.7] [Reference Citation Analysis]
351 Dev A, Patel K, McHutchison JG. Hepatitis C and steatosis. Clin Liver Dis. 2004;8:881-892, ix. [PMID: 15464660 DOI: 10.1016/j.cld.2004.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
352 Bedossa P, Kleiner DE. Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease. In: Chalasani N, Szabo G, editors. Alcoholic and Non-Alcoholic Fatty Liver Disease. Cham: Springer International Publishing; 2016. pp. 223-47. [DOI: 10.1007/978-3-319-20538-0_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
353 Mousa N, Gad Y, Abdel-Aziz A, Abd-Elaal I. Increased α-Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4. Int J Hepatol 2012;2012:636392. [PMID: 22675639 DOI: 10.1155/2012/636392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
354 Watt KD. Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation. Liver Transpl. 2012;18 Suppl 2:S52-S58. [PMID: 22821716 DOI: 10.1002/lt.23515] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
355 Huo TI, Wu JC, Lee PC, Tsay SH, Chang FY, Lee SD. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection. J Clin Gastroenterol. 2000;30:250-254. [PMID: 10777182 DOI: 10.1097/00004836-200004000-00009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
356 Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014;59:2403-2412. [PMID: 24155107 DOI: 10.1002/hep.26905] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 11.5] [Reference Citation Analysis]
357 Goodman ZD, Terracciano LM, Wee A. Tumours and tumour-like lesions of the liver. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 761-851. [DOI: 10.1016/b978-0-7020-3398-8.00014-3] [Cited by in Crossref: 21] [Article Influence: 2.1] [Reference Citation Analysis]
358 Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, Lin R, Samarasinghe D, Liddle C, Mccaughan GW, George J. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004;39:1239-47. [DOI: 10.1002/hep.20207] [Cited by in Crossref: 132] [Cited by in F6Publishing: 119] [Article Influence: 7.3] [Reference Citation Analysis]
359 Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM. Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol. 2005;100:711-715. [PMID: 15743372 DOI: 10.1111/j.1572-0241.2005.40898.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
360 Chow EK, Razani B, Cheng G. Innate immune system regulation of nuclear hormone receptors in metabolic diseases. J Leukoc Biol 2007;82:187-95. [PMID: 17314330 DOI: 10.1189/jlb.1206741] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
361 Nirei K, Matsumura H, Kumakawa M, Matsumoto N, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Int J Med Sci 2017;14:45-52. [PMID: 28138308 DOI: 10.7150/ijms.17202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
362 Patel K, Thompson AJ, Chuang WL, Lee CM, Peng CY, Shanmuganathan G, Thongsawat S, Tanwandee T, Mahachai V, Pramoolsinsap C. Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. J Gastroenterol Hepatol. 2011;26:1182-1188. [PMID: 21410752 DOI: 10.1111/j.1440-1746.2011.06722.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
363 Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol. 2002;16:767-781. [PMID: 12406444 DOI: 10.1053/bega.2002.0329] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.1] [Reference Citation Analysis]
364 Kayali Z, Tan S, Shinkunas L, Voigt M, LaBrecque DR, Stapleton JT, Brown KE, Schmidt WN. Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans. J Viral Hepat 2007;14:11-21. [PMID: 17212639 DOI: 10.1111/j.1365-2893.2006.00764.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
365 Adams LA, Angulo P, Abraham SC, Torgerson H, Brandhagen D. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis. Liver Int. 2006;26:298-304. [PMID: 16584391 DOI: 10.1111/j.1478-3231.2005.01238.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
366 Forrest EH, Thorburn D, Spence E, Oien KA, Inglis G, Smith CA, McCruden EA, Fox R, Mills PR. Polymorphisms of the renin-angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection. J Viral Hepat. 2005;12:519-524. [PMID: 16108768 DOI: 10.1111/j.1365-2893.2005.00630.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
367 Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. [PMID: 19330875 DOI: 10.1002/hep.22759] [Cited by in Crossref: 2134] [Cited by in F6Publishing: 1938] [Article Influence: 164.2] [Reference Citation Analysis]
368 Kim BK, Kim SU, Choi GH, Han WK, Park MS, Kim EH, Park JY, Kim do Y, Choi JS, Yang SC. “Normal” liver stiffness values differ between men and women: a prospective study for healthy living liver and kidney donors in a native Korean population. J Gastroenterol Hepatol. 2012;27:781-788. [PMID: 22098121 DOI: 10.1111/j.1440-1746.2011.06962.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
369 Chen Q, Li ET. Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. Br J Nutr 2005;93:747-54. [PMID: 15975176 DOI: 10.1079/bjn20051388] [Cited by in Crossref: 50] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
370 Li SM, Li GX, Fu DM, Wang Y, Dang LQ. Liver fibrosis evaluation by ARFI and APRI in chronic hepatitis C. World J Gastroenterol 2014; 20(28): 9528-9533 [PMID: 25071348 DOI: 10.3748/wjg.v20.i28.9528] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
371 Nielsen MJ, Karsdal MA, Kazankov K, Grønbaek H, Krag A, Leeming DJ, Schuppan D, George J. Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. Aliment Pharmacol Ther 2016;44:1242-52. [DOI: 10.1111/apt.13819] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
372 Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Petraki K, Hadziyannis E, Pandelidaki H, Zafiropoulou R, Savvas S. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol. 2007;102:634-641. [PMID: 17222326 DOI: 10.1111/j.1572-0241.2006.01025.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
373 Ciccaglione AR, Marcantonio C, Tritarelli E, Equestre M, Vendittelli F, Costantino A, Geraci A, Rapicetta M. Activation of the ER stress gene gadd153 by hepatitis C virus sensitizes cells to oxidant injury. Virus Res. 2007;126:128-138. [PMID: 17368854 DOI: 10.1016/j.virusres.2007.02.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
374 Mühlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Schölmerich J, Hellerbrand C. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003;125:1085-93. [DOI: 10.1016/s0016-5085(03)01213-7] [Cited by in Crossref: 145] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
375 Gholam PM, Domingo AF. Mechanisms of glucose intolerance in patients with chronic hepatitis C: Implications for treatment. Curr Infect Dis Rep 2007;9:110-5. [DOI: 10.1007/s11908-007-0005-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
376 Sanyal AJ;  American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705-1725. [PMID: 12404245 DOI: 10.1053/gast.2002.36572] [Cited by in Crossref: 701] [Cited by in F6Publishing: 659] [Article Influence: 35.1] [Reference Citation Analysis]
377 Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, Manesis EK. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat. 2006;13:303-310. [PMID: 16637860 DOI: 10.1111/j.1365-2893.2005.00677.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 4.5] [Reference Citation Analysis]
378 Harrison SA. Liver Disease in Patients With Diabetes Mellitus. Journal of Clinical Gastroenterology 2006;40:68-76. [DOI: 10.1097/01.mcg.0000190774.91875.d2] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 7.8] [Reference Citation Analysis]
379 Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013;20:35-40. [PMID: 23723729 DOI: 10.4103/2230-8229.108182] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
380 Liu Z, Wei X, Chen T, Huang C, Liu H, Wang Y. Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: A systematic review with meta-analysis. J Gastroenterol Hepatol. 2017;32:548-557. [PMID: 27503423 DOI: 10.1111/jgh.13500] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
381 Puri P, Sanyal AJ. Role of Obesity, Insulin Resistance, and Steatosis in Hepatitis C Virus Infection. Clinics in Liver Disease 2006;10:793-819. [DOI: 10.1016/j.cld.2006.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
382 Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002;123:882-932. [DOI: 10.1053/gast.2002.35514] [Cited by in Crossref: 164] [Cited by in F6Publishing: 127] [Article Influence: 8.2] [Reference Citation Analysis]
383 Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther. 2006;24:1349-1357. [PMID: 17059516 DOI: 10.1111/j.1365-2036.2006.03114.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
384 Lefkowitch JH. Pathology of the liver. Curr Opin Gastroenterol 2000;16:200-7. [PMID: 17023877 DOI: 10.1097/00001574-200005000-00002] [Reference Citation Analysis]
385 Pillai A, Lee V, Wang E, Rinella M, Levitsky J. Factors Associated With Sustained Virological Response in Liver Transplant Recipients With Recurrent Hepatitis C. Transplantation Proceedings 2010;42:3647-51. [DOI: 10.1016/j.transproceed.2010.06.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
386 Tien PC, Kotler DP, Overton ET, Lewis CE, Rimland D, Bacchetti P, Scherzer R, Gripshover B; Study of Fat Redistribution and Metabolic Change in HIV Infection Investigators. Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals. J Acquir Immune Defic Syndr 2008;48:169-76. [PMID: 18285711 DOI: 10.1097/QAI.0b013e3181685700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
387 Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 2013;13:203. [PMID: 23641933 DOI: 10.1186/1471-2334-13-203] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 8.8] [Reference Citation Analysis]
388 Madill J, Arendt B, Aghdassi E, Chow C, Guindi M, Therapondos G, Lilly L, Allard J. Oxidative Stress and Nutritional Factors in Hepatitis C Virus–Positive Liver Recipients, Controls, and Hepatitis C Virus–Positive Nontransplant Patients. Transplantation Proceedings 2010;42:1744-9. [DOI: 10.1016/j.transproceed.2010.03.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
389 Pattullo V, Thein H, Heathcote EJ, Guindi M. Combining semiquantitative measures of fibrosis and qualitative features of parenchymal remodelling to identify fibrosis regression in hepatitis C: a multiple biopsy study: HCV fibrosis regression biopsy study. Histopathology 2012;61:473-87. [DOI: 10.1111/j.1365-2559.2012.04249.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
390 Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, Shiffman ML. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004;2:469-73. [PMID: 15181614 DOI: 10.1016/s1542-3565(04)00164-8] [Cited by in Crossref: 66] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
391 Castéra L, Hézode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut. 2004;53:420-424. [PMID: 14960527 DOI: 10.1136/gut.2002.009936] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 5.2] [Reference Citation Analysis]
392 Cheng CH, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, Hu PJ, Bair MJ. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. J Formos Med Assoc 2021;120:1259-68. [PMID: 33339709 DOI: 10.1016/j.jfma.2020.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
393 Wyatt J, Baker H, Prasad P, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol. 2004;5:402-406. [PMID: 15047745 DOI: 10.1136/jcp.2003.009357] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
394 Bani-sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, Degott C, Pol S. Hepatic steatosis in HIV–HCV coinfected patients: analysis of risk factors. AIDS 2006;20:525-31. [DOI: 10.1097/01.aids.0000210606.63138.f5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 4.4] [Reference Citation Analysis]
395 Negro F. Hepatitis C virus and liver steatosis: when fat is not beautiful. J Hepatol. 2004;40:533-535. [PMID: 15123371 DOI: 10.1016/j.jhep.2004.01.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
396 Chung WJ. [Chronic hepatitis C and insulin resistance]. Korean J Gastroenterol 2012;59:268-74. [PMID: 22544023 DOI: 10.4166/kjg.2012.59.4.268] [Reference Citation Analysis]
397 Valenti L, Pulixi E, Fracanzani AL, Dongiovanni P, Maggioni M, Orsatti A, Gianni C, Fargion S. TNFα genotype affects TNFα release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. Journal of Hepatology 2005;43:944-50. [DOI: 10.1016/j.jhep.2005.05.035] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
398 Pinzani M, Romanelli RG, Magli S. Progression of fibrosis in chronic liver diseases: time to tally the score. J Hepatol. 2001;34:764-767. [PMID: 11434626 DOI: 10.1016/s0168-8278(01)00055-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
399 Modaresi Esfeh J, Ansari-Gilani K. Steatosis and hepatitis C. Gastroenterol Rep (Oxf) 2016;4:24-9. [PMID: 26276502 DOI: 10.1093/gastro/gov040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
400 Vescovo T, Romagnoli A, Perdomo AB, Corazzari M, Ciccosanti F, Alonzi T, Nardacci R, Ippolito G, Tripodi M, Garcia-Monzon C, Lo Iacono O, Piacentini M, Fimia GM. Autophagy protects cells from HCV-induced defects in lipid metabolism. Gastroenterology 2012; 142: 644-653. e3. [PMID: 22155365 DOI: 10.1053/j.gastro.2011.11.033] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
401 Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000;31:828-833. [PMID: 10733535 DOI: 10.1053/he.2000.6253] [Cited by in Crossref: 287] [Cited by in F6Publishing: 285] [Article Influence: 13.0] [Reference Citation Analysis]
402 Balasubramanian A, Groopman JE, Ganju RK. Underlying pathophysiology of HCV infection in HIV-positive drug users. J Addict Dis 2008;27:75-82. [PMID: 18681194 DOI: 10.1300/J069v27n02_09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
403 Perez RM, Ferreira AS, Medina-Pestana JO, Cendoroglo-Neto M, Lanzoni VP, Silva AE, Ferraz ML. Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease? J Clin Gastroenterol. 2006;40:444-448. [PMID: 16721229 DOI: 10.1097/00004836-200605000-00016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
404 Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C, Powell EE. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001;34:314-20. [PMID: 11281562 DOI: 10.1016/s0168-8278(00)00096-9] [Cited by in Crossref: 101] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
405 Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47-S56. [PMID: 12407576 DOI: 10.1002/hep.1840360707] [Cited by in Crossref: 154] [Cited by in F6Publishing: 119] [Article Influence: 7.7] [Reference Citation Analysis]
406 Hwang SJ, Lee SD. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J Gastroenterol Hepatol. 2011;26 Suppl 1:96-101. [PMID: 21199519 DOI: 10.1111/j.1440-1746.2010.06542.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
407 Lawson A, Ryder SD. Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease. Eur J Gastroenterol Hepatol 2006;18:343-7. [PMID: 16538105 DOI: 10.1097/00042737-200604000-00007] [Reference Citation Analysis]
408 Persico M, Masarone M, La Mura V, Persico E, Moschella F, Svelto M, Bruno S, Torella R. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. World J Gastroenterol 2009;15:462-6. [PMID: 19152451 DOI: 10.3748/wjg.15.462] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
409 Castéra L, Hézode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, Dhumeaux D. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003;52:288-92. [PMID: 12524415 DOI: 10.1136/gut.52.2.288] [Cited by in Crossref: 217] [Cited by in F6Publishing: 200] [Article Influence: 11.4] [Reference Citation Analysis]
410 Adinolfi LE, Utili R, Ruggiero G. Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. Hepatology 1999;30:1530-1. [DOI: 10.1002/hep.510300625] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.3] [Reference Citation Analysis]
411 Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796-1807. [PMID: 14724832 DOI: 10.1053/j.gastro.2003.08.029] [Cited by in Crossref: 344] [Cited by in F6Publishing: 329] [Article Influence: 19.1] [Reference Citation Analysis]
412 Cross TJ, Quaglia A, Nolan J, Hughes S, Harrison PM. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection? J Med Virol 2010;82:958-64. [PMID: 20419809 DOI: 10.1002/jmv.21744] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
413 Björnsson E, Angulo P. Hepatitis C and steatosis. Arch Med Res. 2007;38:621-627. [PMID: 17613353 DOI: 10.1016/j.arcmed.2006.09.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
414 Merchante N, Macías J, Ramayo E, Vergara S, García-García JA, Mira JA, Corzo JE, Gómez-Mateos JM, Lozano F, Pineda JA. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. J Viral Hepat. 2006;13:449-456. [PMID: 16792538 DOI: 10.1111/j.1365-2893.2005.00708.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
415 Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53:791-799. [PMID: 21319195 DOI: 10.1002/hep.24123] [Cited by in Crossref: 191] [Cited by in F6Publishing: 183] [Article Influence: 17.4] [Reference Citation Analysis]
416 Aman W, Mousa S, Shiha G, Mousa SA. Current status and future directions in the management of chronic hepatitis C. Virol J. 2012;9:57. [PMID: 22385500 DOI: 10.1186/1743-422x-9-57] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
417 Hézode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, Pawlostky JM, Lotersztajn S, Mallat A. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008;134:432-439. [PMID: 18242211 DOI: 10.1053/j.gastro.2007.11.039] [Cited by in Crossref: 133] [Cited by in F6Publishing: 113] [Article Influence: 8.9] [Reference Citation Analysis]
418 Lo Re V 3rd, Kostman JR. Management of chronic hepatitis C. Postgrad Med J 2005;81:376-82. [PMID: 15937203 DOI: 10.1136/pgmj.2004.025403] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
419 Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010;8:924-33; quiz e117. [PMID: 20713178 DOI: 10.1016/j.cgh.2010.06.032] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
420 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
421 Bowlus CL, Willner I, Zern MA, Reuben A, Chen P, Holladay B, Xie L, Woolson RF, Strange C. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol 2005;3:390-6. [PMID: 15822045 DOI: 10.1016/s1542-3565(05)00082-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
422 MacDonald GA, Bridle KR, Ward PJ, Walker NI, Houglum K, George DK, Smith JL, Powell LW, Crawford DH, Ramm GA. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J Gastroenterol Hepatol. 2001;16:599-606. [PMID: 11422610 DOI: 10.1046/j.1440-1746.2001.02445.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 4.7] [Reference Citation Analysis]
423 Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol. 2006;44:1026-1032. [PMID: 16618518 DOI: 10.1016/j.jhep.2006.02.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 4.0] [Reference Citation Analysis]
424 Silberbogen AK, Ulloa EW, Janke EA, Mori DL. Psychosocial issues and mental health treatment recommendations for patients with hepatitis C. Psychosomatics 2009;50:114-22. [PMID: 19377019 DOI: 10.1176/appi.psy.50.2.114] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
425 Altlparmak E, Köklü S, Yallnklllc M, Yüksel O, Cicek B, Kayacetin E, Sahin T. Viral and host causes of fatty liver in chronic hepatitis B. World J Gastroenterol 2005; 11(20): 3056-3059 [PMID: 15918189 DOI: 10.3748/wjg.v11.i20.3056] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 54] [Article Influence: 3.3] [Reference Citation Analysis]
426 Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl. 2000;6:44-53. [PMID: 10648577 DOI: 10.1002/lt.500060111] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 2.0] [Reference Citation Analysis]
427 Hu K, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18. [DOI: 10.1046/j.1365-2893.2001.00253.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 2.5] [Reference Citation Analysis]
428 Kamada Y, Nakamura T, Funahashi T, Ryo M, Nishizawa H, Okauchi Y, Fukushima J, Yoshida Y, Kiso S, Shimomura I. Visceral obesity and hypoadiponectinemia are significant determinants of hepatic dysfunction: An epidemiologic study of 3827 Japanese subjects. J Clin Gastroenterol. 2009;43:995-1000. [PMID: 19407661 DOI: 10.1097/mcg.0b013e3181962de8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
429 Vento S, Cainelli F. Does hepatitis C virus cause severe liver disease only in people who drink alcohol? The Lancet Infectious Diseases 2002;2:303-9. [DOI: 10.1016/s1473-3099(02)00271-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
430 Kralj D, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol 2016;4:66-75. [PMID: 27047774 DOI: 10.14218/JCTH.2015.00051] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
431 Giannini E, Ceppa P, Botta F, Mastracci L, Romagnoli P, Comino I, Pasini A, Risso D, Lantieri PB, Icardi G. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am J Gastroenterol. 2000;95:3211-3217. [PMID: 11095344 DOI: 10.1111/j.1572-0241.2000.03294.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 1.7] [Reference Citation Analysis]
432 Marchesini G, Forlani G, Bugianesi E. Is liver disease a threat to patients with metabolic disorders? Ann Med. 2005;37:333-346. [PMID: 16179269 DOI: 10.1080/07853890510011445] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
433 Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, Jeffers LJ, Ramcharran D, Ghany MG, Hoofnagle JH; Virahep-C Study Group. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 2006;44:925-35. [DOI: 10.1002/hep.21335] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
434 Hofer H, Bankl HC, Wrba F, Steindl-munda P, Peck-radosavljevic M, Osterreicher C, Mueller C, Gangl A, Ferenci P. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterology 2002;97:2880-5. [DOI: 10.1111/j.1572-0241.2002.07056.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 4.2] [Reference Citation Analysis]
435 Miquilena Colina ME, García Monzón C. [Obesity and liver disease]. Gastroenterol Hepatol 2010;33:591-604. [PMID: 20206411 DOI: 10.1016/j.gastrohep.2009.12.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
436 Saad Y, Ahmed A, Saleh DA, Doss W. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4: . European Journal of Gastroenterology & Hepatology 2013;25:920-5. [DOI: 10.1097/meg.0b013e32835f2726] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
437 Dove LM. A general approach to the management of chronic hepatitis C. Gastroenterology Clinics of North America 2004;33:463-77. [DOI: 10.1016/j.gtc.2004.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
438 Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36:1266-1272. [PMID: 12395339 DOI: 10.1053/jhep.2002.36370] [Cited by in Crossref: 251] [Cited by in F6Publishing: 243] [Article Influence: 12.6] [Reference Citation Analysis]
439 Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect. 2005;11:86-94. [PMID: 15679481 DOI: 10.1111/j.1469-0691.2004.01061.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
440 Rodríguez-Torres M, Ríos-Bedoya CF, Rodríguez-Orengo J, Fernández-Carbia A, Marxuach-Cuétara AM, López-Torres A, Salgado-Mercado R, Bräu N. Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender. J Clin Gastroenterol. 2006;40:358-366. [PMID: 16633110 DOI: 10.1097/01.mcg.0000210105.66994.dc] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
441 Alaei M, Negro F. Hepatitis C virus and glucose and lipid metabolism. Diabetes & Metabolism 2008;34:692-700. [DOI: 10.1016/s1262-3636(08)74606-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
442 Kelly EM, Feldstein VA, Etheridge D, Hudock R, Peters MG. Sonography Predicts Liver Steatosis in Patients With Chronic Hepatitis B: Sonography Predicts Liver Steatosis in Patients With Chronic Hepatitis B. J Ultrasound Med 2017;36:925-32. [DOI: 10.7863/ultra.16.04076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
443 Yasutake K, Kohjima M, Nakashima M, Kotoh K, Nakamuta M, Enjoji M. Nutrition therapy for liver diseases based on the status of nutritional intake. Gastroenterol Res Pract 2012;2012:859697. [PMID: 23197979 DOI: 10.1155/2012/859697] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
444 Heppner DS, Harrison SA. Obesity, insulin resistance, and HCV: Implications for pathogenesis. Curr hepatitis rep 2005;4:153-7. [DOI: 10.1007/s11901-005-0031-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
445 Eguchi Y, Mizuta T, Yasutake T, Hisatomi A, Iwakiri R, Ozaki I, Fujimoto K. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006; 12(4): 556-560 [PMID: 16489668 DOI: 10.3748/wjg.v12.i4.556] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
446 Tyson GL, Richardson PA, White DL, Kuzniarek J, Ramsey DJ, Tavakoli-Tabasi S, El-Serag HB. Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients. J Clin Gastroenterol 2013;47:545-52. [PMID: 23426443 DOI: 10.1097/MCG.0b013e31827244d9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
447 Giannattasio A, Spagnuolo MI, Sepe A, Valerio G, Vecchione R, Vegnente A, Iorio R. Is HCV infection associated with liver steatosis also in children? J Hepatol. 2006;45:350-354. [PMID: 16750584 DOI: 10.1016/j.jhep.2006.03.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
448 Kawamura Y, Arase Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, Yatsuji H, Sezaki H, Akuta N. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med. 2010;123:951-956.e1. [PMID: 20920698 DOI: 10.1016/j.amjmed.2010.05.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
449 Kita Y, Mizukoshi E, Takamura T, Sakurai M, Takata Y, Arai K, Yamashita T, Nakamoto Y, Kaneko S. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism. 2007;56:1682-1688. [PMID: 17998021 DOI: 10.1016/j.metabol.2007.07.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
450 Silva T, Colombo G, Schiavon L. Adiponectin: A multitasking player in the field of liver diseases. Diabetes & Metabolism 2014;40:95-107. [DOI: 10.1016/j.diabet.2013.11.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
451 Hézode C, Lonjon I, Roudot-Thoraval F, Pawlotsky JM, Zafrani ES, Dhumeaux D. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther. 2003;17:1031-1037. [PMID: 12694085 DOI: 10.1046/j.1365-2036.2003.01546.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 4.3] [Reference Citation Analysis]
452 Patel K, Muir A, Mchutchison JG, Patton HM. A Link Between Leptin and Steatosis in Chronic Hepatitis C? Time To Weigh Up The Fats. American Journal of Gastroenterology 2003;98:952-5. [DOI: 10.1111/j.1572-0241.2003.07422.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
453 Serfaty L, Poujol-Robert A, Carbonell N, Chazouillères O, Poupon RE, Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002;97:1807-12. [PMID: 12135040 DOI: 10.1111/j.1572-0241.2002.05793.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 3.0] [Reference Citation Analysis]
454 Sanyal AJ. Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications. Aliment Pharmacol Ther. 2005;22 Suppl 2:48-51. [PMID: 16225473 DOI: 10.1111/j.1365-2036.2005.02596.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
455 Theise ND, Bodenheimer HC, Guido M. Viral Hepatitis. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 372-415. [DOI: 10.1016/b978-0-7020-6697-9.00006-6] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
456 Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol. 2002;37:831-836. [PMID: 12445425 DOI: 10.1016/s0168-8278(02)00301-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
457 Moucari R, Marcellin P, Asselah T. Stéatose au cours de l’hépatite chronique C : rôle de l’insulino-résistance et des facteurs viraux. Gastroentérologie Clinique et Biologique 2007;31:643-54. [DOI: 10.1016/s0399-8320(07)91911-9] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
458 Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095-2100. [PMID: 14697814 DOI: 10.1016/s0140-6736(03)15109-4] [Cited by in Crossref: 604] [Cited by in F6Publishing: 199] [Article Influence: 33.6] [Reference Citation Analysis]
459 Delgado-Borrego A, Kamegaya Y, Jordan SH, Agrawal S, Valim C, Chung RT. HCV synergizes with body weight in the promotion of insulin resistance. J Viral Hepat 2011;18:135-41. [PMID: 20497310 DOI: 10.1111/j.1365-2893.2010.01291.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
460 Lédinghen V, Vergniol J, Foucher J, Merrouche W, Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911-8. [DOI: 10.1111/j.1478-3231.2012.02820.x] [Cited by in Crossref: 206] [Cited by in F6Publishing: 189] [Article Influence: 20.6] [Reference Citation Analysis]
461 Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, Lopez R, Zein NN. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 2008;14:1287-1293. [PMID: 18756451 DOI: 10.1002/lt.21524] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 6.8] [Reference Citation Analysis]
462 Shin JL, Teitel J, Swain MG, Bain VG, Adams PC, Croitoru K, Peltekian K, Schweiger F, Simons ME, Heathcote EJ. A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: Is it safe and useful? Am J Hematol 2005;78:85-93. [DOI: 10.1002/ajh.20263] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
463 Posthouwer D, Makris M, Yee TT, Fischer K, van Veen JJ, Griffioen A, van Erpecum KJ, Mauser-bunschoten EP. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007;109:3667-71. [DOI: 10.1182/blood-2006-08-038349] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
464 Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol 2005;75:550-8. [PMID: 15714492 DOI: 10.1002/jmv.20298] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]